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The basal ganglia are a set of subcortical structures which integrate information
from diverse brain areas to coordinate vital behaviors including movement, reward, and
motivational processes. The striatum is the main input center of the basal ganglia which
sends projections to the output nuclei via two pathways, the direct striatonigral pathway
and the indirect striatopallidal pathway. These two pathways work together to modulate
behavior and imbalance of these pathways can have profound physiological
consequences.
DARPP-32 is a dual function kinase/phosphatase inhibitor which has been shown
to be a key mediator of signaling in both striatonigral and striatopallidal neurons. A
variety of therapeutic agents and drugs of abuse can affect the phosphorylation of
DARPP-32. Psychostimulants such as cocaine increase DARPP-32 phosphorylation at
its main regulatory site, T34. Paradoxically, antipsychotics such as haloperidol also
increase T34 phosphorylation to a similar degree. Despite this similar biochemical
regulation, psychostimulants and antipsychotics have opposing behavioral and clinical
effects. We hypothesized that these drugs act via the same biochemical pathway but in
distinct populations of striatal neurons.

To directly test this idea, we generated BAC transgenic mice which express
epitope tagged DARPP-32 selectively in striatonigral and striatopallidal neurons using
the D1 and D2 receptor promoters. We developed a protocol to immunoprecipitate
DARPP-32 from drug treated mice and study phosphorylation in a cell-type specific
manner. Using this new methodology we demonstrate that the increases in T34
phosphorylation with acute cocaine and haloperidol are restricted to striatonigral and
striatopallidal neurons, respectively. Additionally, we show that the changes in DARPP32 phosphorylation induced by a variety of drugs targeting the striatum have cell-type
specific patterns.
In a complimentary approach, we generated conditional knock-out mice in which
DARPP-32 is selectively deleted in striatonigral or striatopallidal neurons. This allowed
us to study the behavioral consequences of alteration in the direct and indirect pathways
on psychostimulant and antipsychotic mediated locomotor behavior. These studies
provided direct evidence for the theory that the direct and indirect pathways exert
opposing influences on locomotor behavior. Additionally, we showed that dopamine can
differentially modulate activity in these pathways resulting in a synergistic stimulation of
locomotor activity.
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Chapter 1
INTRODUCTION

1

The Basal Ganglia
The basal ganglia (BG) are a set of subcortical structures involved in coordinating
information from sensorimotor, motivational and cognitive brain areas to control
behaviors such as movement and reward learning. Signals from the cortex, mid-brain
and limbic regions are processed and integrated through the basal ganglia which in turn
send this integrated information back to the cortex and brain stem to drive behavior.
Disruption in BG signaling can have profound consequences on an organism’s behavior.
Parkinson’s disease and Huntington’s disease are neurodegenerative diseases affecting
structures in the BG which result in debilitating disruption of coordinated movement and
cognition. The maladaptive reward learning associated with drug addiction has been
linked to alterations in cellular processes in particular areas of the BG. Psychiatric
disorders such as schizophrenia, obsessive-compulsive disorder, and attention deficit
hyperactivity disorder have also been connected to the BG, involving imbalances in
neurotransmitter systems within this brain area. A thorough understanding of the normal
and disrupted function of the BG is therefore useful to gain insight into a number of
diverse and critical brain processes.
The BG consist of several interconnected structures which include the striatum,
comprised of the caudate/putamen and nucleus accumbens, the external and internal
segments of the globus pallidus, the subthalamic nucleus, and the substantia nigra (Figure
1.1). Together with the cortex and thalamus, the BG participate in a circuit which begins
with topographically mapped glutamatergic afferents from the cortex and thalamus to the
striatum. Striatal neurons then send GABA-ergic collaterals within the striatum and
primary projections to BG output nuclei via two pathways. The direct striatonigral
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pathway sends monosynaptic projections to the substantia nigra pars reticulata (SNr) and
the globus pallidus internal segment (GPi, entopeduncular nucleus (EPN) in rodents).
The indirect striatopallidal pathway projects to the globus pallidus external segment
(GPe) which in turn sends GABA-ergic axons to the subthalamic nucleus (STN). The
STN sends excitatory glutamatergic projections back to the GPe as well as to the output
nuclei, the GPi/SNr. GPi/SNr neurons project to several thalamic nuclei which then
complete the circuit by innervating prefrontal, premotor, and motor cortical areas. In
addition to the cortex and thalamus, the hippocampus and amygdala also send
topographically organized glutamatergic input to the striatum which is most dense in
ventral striatal regions.
In addition to transmission via glutamate and GABA, the BG also relies on
signaling by modulatory neurotransmitters, among which dopamine plays an essential
role. There are several different dopaminergic pathways within the basal ganglia-cortical
circuit which are associated with subsets of connections mediating different aspects of
BG function. The nigrostriatal pathway sends dopaminergic projections from the SNc to
the dorsal striatum and is essential for coordinated voluntary movement. It is the SNc
dopaminergic neurons which degenerate in Parkinson’s disease resulting in disruption of
motor activity. The mesolimbic pathway is comprised of dopaminergic projections from
the ventral tegmental area to the nucleus accumbens and this system is largely involved in
motivation, emotion, and reward processes. Another set of dopaminergic projections
from the VTA to the limbic cortex known as the mesocortical pathway, is associated with
working memory, learning and reward.
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In addition to glutamate and dopamine, striatal neurons respond to a variety of
other neurotransmitters including serotonin, adenosine, acetylcholine and opiates,
discussed in more detail below. Taken together, the combination of interconnections
between BG structures, the inputs from a wide-range of brain regions, and the ability to
respond to a varied array of signals, endows the BG with the ability to integrate diverse
information in a selective and complex way.
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Figure 1.1 Basal Ganglia Circuitry
Schematic drawing of the connections between structures of the basal ganglia. Green arrows indicate
excitatory glutamatergic projections, red arrows indicate GABA-ergic inhibitory projections, and blue
arrows represent dopaminergic projections. Abbreviations: D1, dopamine receptor type 1; D2, dopamine
receptor type 2; Ach, acetylcholinergic interneuron; GABA, GABA-ergic interneuron; GPe, globus pallidus
external segment; GPi, globus pallidus internal segment; STN, subthalamic nucleus; SNr, substantia nigra
pars reticulata; SNc, substantia nigra pars compacta; VTA, ventral tegmental area. Adapted from
(Svenningsson et al., 2004).
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The Striatum
The striatum is the main input center for the BG which responds to and integrates
signals from a variety of brain areas and neurotransmitter systems. The striatum is
therefore an excellent model system for studying neuronal signal transduction and
integration. The striatum is mainly comprised of medium spiny neurons (MSNs) which
represent 90-95% of all cells in this structure (Kemp and Powell, 1971). These neurons
contain a large number of dendritic spines which are the primary sites receiving
dopaminergic and glutamatergic input. MSN’s are GABA-ergic and send axons
collaterally within the striatum and project via the direct and indirect pathways to the
output structures of the BG. The division of MSN’s into direct and indirect subpopulations is accompanied by differences in the expression of neuropeptides and
neurotransmitter receptors in each cell type. Direct pathway neurons express substance P
and dynorphin and preferentially express type 1 dopamine receptors (Gerfen et al., 1990).
Indirect pathway MSN’s express enkephalin, type 2 dopamine receptors, and adenosine
type 2 receptors (Gerfen et al., 1990).
In addition to MSNs, the striatum contains several classes of interneurons defined
by their physiology, morphology, and expression of specific markers. Striatal
interneurons fall into four main categories, one class of large cholinergic neurons which
represent the main source of acetycholine (Ach) in the striatum, and three types of
GABA-ergic interneurons which express either parvalbumin, calretinen, or nitric oxide
synthase (NOS) and NADPH-diaphorase (Kawaguchi et al., 1995). These interneurons
receive input from the cortex, SNc, GPe as well as from other interneurons and make
synapses on MSN’s where they can strongly regulate action potential firing (Tepper et al.,
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2004). The striatum, therefore, can be viewed as a site of integration not only at the level
of varied inputs converging on individual cells but also at the level of signal integration
across networks of striatal neurons.

Divisions of the striatum
Although the different classes of striatal projection neurons are homogeneously
expressed throughout the striatum, anatomical divisions can be made within the striatum
based on differences in neurochemistry, efferent and afferent connections, physiology,
and contributions to BG-mediated behavior. The three major divisional categories are
dorsal versus ventral striatum, patch versus matrix compartments, and direct versus
indirect projection pathways.
Dorsal versus Ventral Striatum. The dorsal-ventral division of the striatum was
originally based on differences in afferent connections, whereby the dorsal region
receives somatotopically organized sensorimotor-related information from the cortex and
dopaminergic innervation primarily from the SNc (Donoghue and Herkenham, 1986;
Kitai et al., 1976). The ventral striatum, on the other hand, receives visceral and limbic
related afferents with a higher density of inputs from the amygdala, hippocampus, and
VTA (Voorn et al., 2004). The intermediate zone receives polymodal information from
the thalamus as well as input from higher associational cortical centers (Voorn et al.,
2004). These divisions are loosely based, however, as there are no strict anatomical
boundaries between these regions and innervation by all afferent brain regions is found
throughout the striatum. It has also recently been suggested that a more accurate
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dorsal/ventral division of the striatum may be along a dorsolateral to ventromedial axis
(Voorn et al., 2004).
Distinctions between the dorsal and ventral striatum are also made regarding their
function and relative contribution to behavioral processes. The dorsolateral striatum has
been associated with procedural, stimulus-response, and spatial learning, whereas the
ventromedial striatum is involved in motivation and reward learning and is the primary
site of action for drugs of abuse. Within the ventral striatum, the nucleus accumbens can
be further subdivided into core and shell regions which differ in their efferent and
afferents connections. There has been significant research in the field of drug abuse to
examine the contributions of the core versus shell in different biochemical and behavioral
correlates of drug addiction. One conclusion from this work is that the core controls
responses to conditioned reinforcers whereas enhancement of this reinforcement by drugs
of abuse may depend on the shell (Parkinson et al., 1999).
Patch and Matrix Compartments. The striatum can also be divided into patch and
matrix compartments which were regions originally identified histologically as rich or
poor in acetycholinsterase staining (AchE) (Graybiel and Ragsdale, 1978). The AchE
poor striosomes or patches were later shown to correspond to small striatal regions rich in
µ-opiod receptor mRNA and protein (Herkenham and Pert, 1981). The patch and matrix
areas differ in their connectivity whereby the larger matrix compartment (representing
80-90% of striatal volume) receives afferents from layer V cortical neurons and sends
efferents to the GP and SNr (Donoghue and Herkenham, 1986). The striatal matrix is
also associated with largely sensorimotor information. The patch compartment receives
afferents from limbic areas as well as cortical layers Vb and VI and sends efferents to the
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SNc which can modulate dopaminergic input into the striatum (Graybiel, 1990).
Although the patch/matrix distinction is not completely rigid, it suggests that there are
unique biochemically and anatomically defined sub-regions within the striatum which
likely have selective roles in the functions of this brain region.
Direct and Indirect Pathway Projections. As mentioned previously, a major
characteristic of the striatum is the division of its efferents into the direct striatonigral and
indirect striatopallidal pathways. The direct pathway is comprised of projections from a
sub-class of GABA-ergic MSNs which express D1 receptors and directly innervate the
SNr. Indirect pathway neurons preferentially express D2 receptors and project to the
GPi/SNr via two intermediate structures, the GPe and STN. These anatomically defined
cell populations are receiving more attention as it becomes increasingly clear that they
have distinct physiological and signaling properties and that they can be modulated
independently to result in different behavioral outcomes. In the normal state, these
output pathways are highly regulated and work synergistically to produce coordinated
effects on behavior. In the case of disruption or imbalance in signaling, such as occurs in
Parkinson’s disease, there are unique maladaptations which occur in each pathway that
may have important consequences for targeting therapies to this brain area (Albin et al.,
1989; Gerfen, 2000).
Studies dissecting the relative contributions of these pathways to behavioral or
biochemical processes have been limited by the fact that these two types of projection
neurons are morphologically indistinguishable and anatomically intermixed. Only
recently have novel techniques emerged, largely based on genetically modified mouse
technology, which allow selective identification, purification, and/or targeting of these
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cells (Gong et al., 2003; Heintz, 2001). Studies utilizing these mice have revealed
important differences between striatonigral and striatopallidal neurons which were not
appreciated with conventional techniques. Chapters three and four of this thesis will
present further data revealing important differences in intracellular signaling processes
between these two cell populations.

Striatal neurotransmitter systems
As stated previously, the striatum is innervated by an abundance of
neurotransmitters and neuromodulators which are integrated at the level of the single cell
and in the context of the entire BG. Striatal cells are therefore an excellent system to
study signal transduction, specifically the interactions between fast and slow signaling
pathways (Figure 1.2). Fast synaptic responses occur within milliseconds and are due to
the rapid influx of charged ions into the cell which depolarize or hyperpolarize the cell
membrane, ultimately making a cell more or less likely to fire an action potential
(Greengard, 2001). Slow transmission, on the other hand, requires seconds to minutes,
and occurs largely through G-protein coupled receptors which are linked to a vast array
of second messengers and signaling molecules including protein kinases and
phosphatases (Greengard, 2001). Signaling via these second messengers allows multiple
points of convergence or inhibition between the numerous signaling molecules that act on
the striatum and provides an opportunity to study the complex interactions between these
pathways.
In order to respond to a vast array of neurotransmitters and neuromodulators,
striatal neurons express a wide variety of receptors and ion channels. These include
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ionotropic and metabotropic glutamate receptors, GABA receptors, several classes of
serotonin receptors, adenosine receptors, opiate receptors, and several types of dopamine
receptors which will be discussed in more detail in the next section. Here I will present a
brief overview of the non-dopaminergic signaling pathways with regard to their role in
striatal function.

Figure 1.2 Signaling Pathways in Striatal Medium Spiny Neurons
Striatal medium spiny neurons respond to a variety of neurotransmitters, therapeutic drugs, and drugs of
abuse which are integrated at the level of direct receptor interactions and second messenger cascades.
Green arrows represent excitatory actions, red arrows represent inhibitory actions. See text for
abbreviations. Adapted from (Greengard, 2001)
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Glutamate. Glutamatergic input from the cortex and thalamus provides the
primary excitatory drive to striatal neurons. Glutamate acts on AMPA and NMDA
ionotropic receptors expressed on striatal cells which control the influx of sodium and
calcium into these neurons. AMPA and NMDA receptors are the primary players
mediating cellular learning and memory processes which are known as long-term
potentiation (LTP) and long-term depression (LTD). LTP and LTD are processes
whereby coordinated periods of high frequency (LTP) or low frequency (LTD) glutamate
input combined with a permissive post-synaptic environment result in long-term changes
in synaptic strength and responses to future stimulation. The induction phase of these
processes relies largely on local changes in the phosphorylation of AMPA and NMDA
receptors which changes their functional properties and/or trafficking to the membrane
(Malinow and Malenka, 2002; Raymond, 2007). Late-phase LTP and LTD, however,
require gene transcription and protein synthesis (Mameli et al., 2007; Raymond, 2007).
LTP and LTD are important forms of synaptic plasticity expressed at
corticostriatal synapses and may underlie primary striatal functions such as motor and
reward learning, and cognitive performance (Calabresi TINS 2007). Disruptions in
normal LTP and LTD processes are seen in response to drugs of abuse and in
maladaptive responses to drugs used to treat Parkinson’s disease (Kauer and Malenka,
2007; Picconi et al., 2003; Ungless et al., 2001). Although striatal LTP and LTD are
primarily mediated by AMPA and NMDA receptor activation, these forms of plasticity
also critically depend on input from striatal neuromodulators such as dopamine,
acetylcholine, endocannabinoids, and nitric oxide as discussed below (Surmeier et al.,
2007).
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In addition to ionotropic transmission, glutamate also acts via metabotropic
glutamate receptors (mGluRs) which are expressed in the striatum. mGluRs are divided
into three groups based on their sequence homology and coupling to G-proteins. Group I
mGluR1 receptors are expressed post-synaptically on MSNs and interneurons of the
striatum as well as pre-synaptically on dopaminergic neurons of the SNc. mGluR1
receptors are coupled to Gq proteins which can activate the phospholipase C
(PLC)/diacylglycerol (DAG)/inositol triphosphate (IP3) cascade which increases
intracellular calcium levels and protein kinase C (PKC) activity. In dopaminergic
neurons of the SNc, activation of mGluR1 receptors on axon terminals suppresses
dopamine release to the striatum, likely due to the activity of calcium-activated potassium
channels (Zhang and Sulzer, 2003). mGluR5 receptors are expressed in indirect
striatopallidal MSNs where they couple to Gq and can amplify NMDA signaling (Conn et
al., 2005). mGluR5 receptors have recently been shown to physically interact with A2A
receptors acting synergistically to promote downstream signaling pathways including the
activation of mitogen-activated protein kinase (MAPK) which in turn activate gene
expression in these cells (Ferre et al., 2002; Nishi et al., 2003).
Group II mGluRs (mGluR2 and mGluR3) receptors are also involved in striatal
signaling. They are expressed presynaptically on corticostriatal nerve terminals where
they can negatively regulate glutamate release onto striatal cells (Lovinger and McCool,
1995). In addition to expression within the striatum, ionotropic and metabotrobic
glutamate receptors are expressed either pre- or post-synaptically throughout the basal
ganglia which contributes to a complex network of signaling by glutamate in this brain
region.
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GABA. Ionotropic GABAA and metabotropic GABAB receptors are expressed in
the striatum and respond to GABA released from MSN axon collaterals and striatal
interneurons. GABAA receptors are ligand-gated ion channels that allow hyperpolarizing
chloride ions to enter the cell which generates inhibitory post synaptic potentials and
counter-balances glutamatergic transmission. GABAA receptors are expressed postsynaptically on MSNs. Recent studies have suggested that GABAA receptors may be
upregulated in the drug addicted state serving as a homeostatic mechanism to
counterbalance increases in dopaminergic transmission (Heiman et al., 2007; Volkow et
al., 1998). Metabotropic G-protein coupled GABAB receptors are expressed in striatal
interneurons, MSNs, and in GP, SN and VTA neurons (Waldvogel et al., 2004). Recent
studies suggest that GABAB receptors expressed in dopaminergic cells play an important
role in regulating dopamine release in the striatum and therefore mediating the rewarding
properties of drugs of abuse (Vacher et al., 2006).
Serotonin. The serotonergic system plays an important role in the regulation of
emotion, mood, reward and cognition. Serotonin imbalance is implicated in several
common psychiatric disorders including depression, schizophrenia, and drug addiction
and the serotoninergic system is the target for many of the current medications used to
treat these types of disorders. The prefrontal cortex and hippocampus are well studied
sites of serotonin action. However, the important role of serotonin signaling in the
striatum is becoming increasingly clear (Svenningsson et al., 2002a; Svenningsson et al.,
2002b; Zhang et al., 2007). Medium spiny neurons express several sub-types of
serotonin receptors including 5-HT1B, 5-HT1F, 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, and 5-HT6
(Svenningsson et al., 2004). All of these receptors are metabotropic, with the exception
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of 5-HT3 which is ionotropic, and activate a variety of intracellular signaling pathways
which converge with second messenger systems initiated by dopamine and other
neurotransmitters. Striatal serotonin receptors act primarily via the following second
messenger systems: 5-HT1B/E receptors decrease cyclic AMP (cAMP) formation, 5HT2A/C receptors increase DAG and IP3 production, 5-HT3 receptors increase Na+ and
Ca+ influx, and 5-HT4 and 5-HT6 receptors increase cAMP production (Svenningsson et
al., 2004). Two recent studies showed that Prozac, a commonly prescribed antidepressant drug, acts via 5-HT4 and 5-HT6 receptors in the striatum to increase cAMP
and protein kinase A (PKA) signaling, a pathway which is also important in dopamine
signaling (Svenningsson et al., 2002a; Svenningsson et al., 2002b).
Adenosine. Like dopamine and serotonin, adenosine has an important modulatory
role in the striatum. Adenosine is primarily formed via the breakdown of intracellular
ATP which is transported to the extracellular space via transporter molecules. Released
adenosine acts via two types of G-protein coupled metabotropic receptors, A1 and A2A,
which are highly expressed in the brain (Fredholm et al., 2005). The A1 receptor subtype is widely expressed throughout the brain, in both types of striatal projection neurons,
and on pre-synaptic dopaminergic nerve terminals (Ferre et al., 1997). A1 receptors are
coupled to Gi proteins which inhibit cAMP and PKA signaling. A1 receptors have
recently been shown to modulate dopamine signaling in both direct and indirect MSN’s
via their influence on pre-synaptic dopamine release as well as through G-protein
mediated second messenger signaling (Yabuuchi et al., 2006).
A2A receptors, on the other hand, are highly expressed in the striatum where they
are selectively localized to indirect striatopallidal MSN’s (Schiffmann et al., 1991). A2A
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receptors are coupled to Golf proteins which stimulate the adenylyl cyclase
(AC)/cAMP/PKA cascade (Kull et al., 2000). A2A receptors form heteromeric complexes
with D2 dopamine receptors in striatopallidal neurons where they can oppose D2 R
signaling via modulation of ligand binding affinity and through opposing action on the
AC/cAMP/PKA cascade (Ferre et al., 1991; Yabuuchi et al., 2006). It was recently
discovered that the mechanism of action of the widely used psychostimulant, caffeine, is
via antagonism of A2A receptors (Fredholm et al., 1999). Inhibition of A2ARs by caffeine
is “pro-dopaminergic” since it relieves the A2AR-mediated inhibition of D2 receptor
signaling (Lindskog et al., 2002). A role for A2A receptor signaling in Parkinson’s
disease is also becoming increasingly clear and A2A receptor antagonists are being touted
as potential non-dopaminergic therapies for PD due to their lower risk for debilitating
side-effects and potential neuroprotective properties (Schwarzschild et al., 2006).
Acetylcholine. As mentioned previously, acetylcholine is released in the striatum
by large cholinergic interneurons and a proper balance between dopamine and
acetylcholine is necessary to govern coordinated movement. Several classes of nicotinic
and muscarinic acetylcholine receptors (AchRs) are expressed in specific pre- and postsynaptic striatal compartments where they regulate striatal signaling. α4Β2 and α7
nicotinic AChRs are found at pre-synaptic dopaminergic and glutamatergic nerve
terminals respectively and stimulation of these receptors induces either DA or glutamate
release (Hamada et al., 2005). It is thought that the rewarding and addictive properties of
nicotine are mediated by direct action of this drug at nAChRs resulting in increased
dopamine release in the striatum.
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In addition to nicotinic receptors, muscarinic G-protein coupled acetylcholine
receptors also play an important role in BG signaling. Pre-synaptic muscarinic M5
receptors are expressed in SNc dopaminergic cells and can facilitate the release of
dopamine (Zhang et al., 2002) . M4 receptors are expressed abundantly on MSNs and
facilitate dopamine release likely by inhibiting GABA-ergic negative feedback to
dopaminergic neurons (Zhang et al., 2002). M3 receptors, on the other hand, are
expressed at low levels in MSNs but can also inhibit dopamine release (Zhang et al.,
2002). M1 ACh receptors located post-synaptically on MSNs were recently shown to be
involved in corticostriatal LTD whereby lowering M1 receptor tone promoted this type of
plasticity via disinhibition of L-type calcium channels (Wang et al., 2006).
Opiates, nitric oxide, and endocannabinoids. The roles of the neurotransmitters
described above, either in the striatum or in other brain systems, have been well studied.
In addition to these factors, signaling molecules outside of the classical categories have
also been shown to exert important modulatory roles in the striatum. Among these are
the neuropeptide opiates, the gaseous signaling molecule nitric oxide, and the membrane
lipid-derived endocannabinoids which were recently found to play a role in striatal
function.
Endogenous opiates regulate striatal function by indirect action on dopaminergic
neurons and by direct activity at opioid receptors located post-synaptically on MSNs.
Opioid receptors are highly expressed in the striatum where κ-opioid receptors are
expressed primarily on dopaminergic nerve terminals, and µ- and δ-receptors are
expressed on MSNs (Schoffelmeer et al., 1986). µ-receptors are selectively enriched in
direct pathway striatonigral neurons where they are co-localized with D1 receptors and
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negatively regulate D1 receptor signaling (Georges et al., 1999). δ-receptors are
expressed in interneurons as well as in indirect striatopallidal MSNs where they can
counteract signaling via A2A receptors (Lindskog et al., 1999).
Striatal nitric oxide (NO) is generated by neuronal nitric oxide synthase-(nNOS)expressing interneurons upon stimulation of dopamine type 5 receptors expressed in these
interneurons (Centonze et al., 2003). NO diffuses across the cell membrane where it
activates soluble guanylyl cyclase, thereby increasing cGMP levels, and protein kinase G
(PKG) activity. Via this pathway, NO has been shown to be involved in striatal synaptic
plasticity via regulation of the induction phase of LTD in MSNs (Centonze et al., 2003).
In addition to the modulation of synaptic plasticity by opiates and NO,
endogenous cannabinoids (ECBs) have emerged as additional regulators of LTD in the
striatum as well as in other brain areas (Calabresi et al., 2007). ECBs are synthesized
from membrane derived lipid precursors released from post-synaptic MSNs upon D2 R
activation. These signaling molecules then bind to CB-1 receptors located in
glutamatergic axon terminals which serve to suppress glutamate release and induce LTD
in corticostriatal synapses (Yin and Lovinger, 2006).
Taken together these descriptions provide a brief overview into the variety and
complexity of non-dopaminergic signaling pathways in the striatum. All of these
pathways are linked to each other either via direct receptor interactions, modulation of
pre-synaptic neurotransmitter release, or interactions at the level of second messengers.
A common theme in these signaling pathways is that they are all somehow connected
back to dopamine which appears to be either modulating or modulated by these signaling
molecules. In the next section I will discuss in more detail what is known about
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dopamine in the striatum and the signaling properties of dopamine receptors which are
key regulators of basal ganglia function.

III. Dopamine
Dopamine (DA) belongs to the class of catecholamine neurotransmitters which
also includes epinephrine (E) and norepinephrine (NE, also known as noradrenaline).
These three neurotransmitters are synthesized from the amino acid tyrosine via a series of
enzymatic steps. The first enzyme in the pathway is tyrosine hydroxylase (TH) which
converts tyrosine to L-dihydroxy-phenylalanine (L-DOPA) which is the rate limiting step
in DA and NE synthesis (Holtz, 1959). TH is present in all catecholamine-producing
neurons and is commonly used as a histological marker for these cell types. L-DOPA is
then converted to dopamine by a carboxylase. In NE and E expressing neurons, two
additional enzymes are required to convert DA to NE and NE to E. L-DOPA is the
“gold-standard” drug used to rescue the effects of dopamine loss associated with
Parkinson’s disease (PD) and will be discussed in more detail below.
Dopamine is released by several populations of midbrain and forebrain neurons.
The A8-10 mid-brain dopaminergic cell groups include the SNc and VTA which send
ascending projections to the striatum, cortex and limbic system. The A11-14 cell
populations arise from the hypothalamus and wall of the third ventrical and send
descending projections to the autonomic areas of the brain stem and spinal cord, as well
as regulate neuroendocrine function. There are additional dopaminergic cell groups
(A15-17) located in olfactory structures and in the retina.
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This work will focus on the SNc and VTA dopaminergic projection neurons
which innervate the BG. These ascending dopaminergic inputs are linked to several
important brain processes including control of voluntary movement, reward learning, and
motivational processes. A large body of behavioral, biochemical, and
electrophysiological work has been devoted to understanding the precise aspects of these
processes which are controlled by dopamine. Dopamine’s role in motor function has
been long recognized and there are several current hypotheses regarding DA’s function in
reward. Prevailing views suggest that DA is critical for reinforcement processes which
are the strengthening of stimulus-response and stimulus-reward associations (Wise, 2004).
DA has also been shown to be involved in priming, motivational arousal, and reward
prediction (Wise, 2004). Many of these functions require learning and memory processes
and DA plays an essential role in modulating LTP and LTD, the cellular correlates of
learning, which will be further discussed below (Calabresi et al., 2007).

Dopamine Receptors
Dopamine’s actions are carried out by five sub-types of DA receptors selectively
expressed in discrete brain regions. Dopamine receptors are seven transmembrane
domain metabotropic receptors which are coupled to G-proteins. The D1-class of
receptors includes the D1 and D5 sub-types which couple to Gs proteins and activate
adenylyl cyclase (AC), the enzyme that converts ATP to cAMP (Stoof and Kebabian,
1981). cAMP activates a major effector enzyme, protein kinase A (PKA). Activated
PKA phosphorylates a variety of intracellular targets such as neurotransmitter receptors,
ion channels, transcription factors, and signaling molecules which changes their signaling
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properties and can influence cellular excitability. Protein phosphorylation has been
shown to be a key mechanism underlying synaptic signal transduction as it allows
relatively fast modification of protein targets without the need for further transcriptional
or translational processes (Greengard 2001 Science). The D2 class of receptors includes
D2 R, D3 R and D4 R which are coupled to Gi proteins and inhibit AC, thereby
decreasing cAMP and PKA activity (Stoof and Kebabian, 1981). D2 receptors can also
elevate intracellular calcium levels and activate a phospholipase C (PLC)/protein
phosphatase-2b (PP-2B) cascade (Nishi et al., 1997). D2 receptors have been shown to
have a higher affinity for dopamine than D1 R which may impact the relative
contribution of signaling via these receptors in low and high dopamine states (Hamada et
al., 2004; Missale et al., 1998).
D1 receptors show widespread neocortical expression including the prefrontal
cortex (PFC) and striatum. D5 receptors are concentrated in the hippocampus and
entorhinal cortex (EC) with very low expression in the striatum. D2 receptors are highly
expressed in the striatum where they are found both post-synaptically on MSNs and presynaptically as autoreceptors on dopaminergic nerve terminals. D2 receptors are also
expressed at low levels in the hippocampus, EC, amygdala, and weakly in the PFC. D2
receptors exist as two different slice variants termed D2short and D2long which are
differentially expressed pre-synaptically (D2short) or post-synaptically (D2long) (Centonze
et al., 2004). D3 Rs are expressed in the striatum where they are concentrated in the
ventral striatum/nucleus accumbens. D3 and D4 receptors are also expressed in limbic
structures including the amygdala, hippocampus and PFC (Guillin et al., 2007; Sealfon
and Olanow, 2000).

21

Within the striatum, post-synaptic D1 and D2 receptors are largely segregated to
the two populations of MSNs comprising the direct striatonigral, and indirect
striatopallidal pathways (Gerfen et al., 1990). The early evidence for this segregation
was based on retrograde labeling from BG output structures and histochemical staining
with cell specific markers (Deng et al., 2006; Gerfen and Young, 1988). Current
techniques relying on genetically targeted constructs using the D1R and D2R promoters
have also verified this segregation (Gong et al., 2003). Studies utilizing both BAC
transgenic mice as well as traditional knock-outs and knock-ins have shown differential
responses to various agents in D1R and D2R-expressing cell populations (Day et al.,
2006; Gantois et al., 2007; Lee et al., 2006; Moratalla et al., 1996).
Despite strong evidence for segregation of D1R and D2Rs in the striatum, some
studies have suggested varying degrees of co-localization (Aizman et al., 2000; Surmeier
et al., 1996). These studies relied on techniques such as immunohistochemistry and RTPCR which are sensitive and can have problems with background contamination.
Additionally, these studies were performed in cultured striatal neurons which may not
accurately represent the in vivo situation. The work presented here in subsequent
chapters provides additional evidence that D1 and D2 receptors are segregated to
different striatal cell populations.

Dopamine Receptors and Synaptic Plasticity
It is widely accepted that one of the major functions of dopamine is to modulate
glutamatergic signaling. In the case of the striatum this involves modulation of excitatory
corticostriatal input. Glutamatergic and dopaminergic axons terminate of the head and
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neck, respectively, of dendritic spines on medium spiny neurons (Chase and Oh, 2000).
As mentioned previously, the striatum is involved in several types of learning and
memory processes and balanced striatal synaptic plasticity including LTP and LTD is
essential for its function. Electophysiological studies have examined the relative
contributions of D1 and D2 receptors to these processes.
D1 receptors have been shown to interact with NMDA-type glutamate receptors
which impacts the trafficking and function of each receptor in a bi-directional manner
(Lee et al., 2002; Scott et al., 2002). Via several different pathways, dopamine can either
enhance or inhibit NMDA signaling based on the depolarization state of the neuron
(Surmeier et al., 2007). Acting through the cAMP/PKA pathway, D1R signaling has
been shown to increase phosphorylation of NMDA receptors and calcium channels which
can enhance glutamate-induced currents (Flores-Hernandez et al., 2002). It is thought
that this mechanism may underlie the D1 receptor activation of LTP, a process which is
lost by treatment with D1R antagonists, or in D1 receptor knock-out mice (Calabresi et
al., 2007).
D2 receptors, conversely, have an inhibitory effect on LTP and are known to be
vital in the induction of LTD. D2R activation leads to dephosphorylation of the GluR1
subunit of the AMPA receptor which reduces glutamate-mediated currents and can
promote trafficking of the receptor out of the membrane (Hakansson et al., 2006).
Stimulation of D2 receptors can also lead to diminished pre-synaptic release of glutamate
(Yin and Lovinger, 2006). As mentioned previously, D2 receptors play an important role
in striatal LTD. D2 receptors expressed in cholinergic interneurons regulate
acetylcholine release, while D2Rs expressed post-synaptically on MSNs are important in
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facilitating endocannabinoid release, both essential mediators of LTD (Calabresi et al.,
2007).

Dopamine Receptors and Locomotion
In the case of the D1 receptor, the classical model of basal ganglia circuitry
predicts that dopamine stimulation of D1Rs on direct pathway neurons will increase
locomotion. This is due to the excitatory action of dopamine acting via D1Rs in direct
pathway neurons which results in increased GABA-ergic input to the GPi/SNr. This
inhibition of the GPi/SNr in turn relieves inhibition of thalamic neurons thereby
facilitating excitation of cortical motor neurons (Figure 1.3). In agreement with this,
application of selective D1R agonists increases locomotor behavior (Desai et al., 2005).
Dopamine acting via D2 receptors is also expected to increase locomotor activity
by the following mechanism. Stimulation of D2Rs is inhibitory in indirect pathway cells,
resulting in decreased GABA-ergic input to the GPe. The GPe can then exert a strong
inhibitory influence on the STN resulting in less excitation of the GPi/SNr. This has the
effect of reducing the inhibitory influence of the GPi/SNr on excitatory thalamocortical
neurons thereby facilitating locomotion (Figure 1.3). As a result, agents which block D2
receptors such as antipsychotics, decrease locomotion and in some cases result in
catalepsy, characterized by loss of voluntary movement and muscular rigidity.
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Figure 1.3 Regulation of Locomotor Behavior by Direct and Indirect Pathway Neurons
Schematic of the excitatory and inhibitory connections of the basal ganglia output pathways controlling
locomotion. Minus signs indicate GABA-ergic inhibitory connections, plus signs indicate glutamatergic
excitatory connections. Bolded and circled plus and minus signs indicate increased excitation or inhibition
in response to dopamine. Abbreviations: DA, dopamine; D1R, type 1 dopamine receptor; D2R, type 2
dopamine receptor; SNr, substantia nigra pars reticulata; TH, thalamus; Ctx, cortex; GPe, globus pallidus
external segment; STN, subthalamic nucleus.

Dopamine Receptors in the Action of Psychostimulants
Nearly all drugs of abuse have been shown to be dependent on or alter
dopaminergic signaling (Nestler, 2001). Psychostimulant drugs have direct actions on
the dopamine system by enhancing levels of synaptic dopamine. This enhancement
occurs either by blocking the re-uptake of dopamine by the pre-synaptic dopamine
transporter (DAT) or by facilitating the release of dopamine from synaptic vesicles.
Dopamine receptor signaling is essential for mediating both the locomotor stimulant and
addictive properties of these drugs.
Studies with D1 receptor knock-out (D1R KO) mice have shown that these mice
have altered sensitization and locomotor responses to cocaine (Xu et al., 2000). D1R KO
mice have also been shown to have reduced or absent biochemical responses to
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psychostimulants including blunted dynorphin and cfos responses (Moratalla et al., 1996).
Activation of the cAMP/PKA pathway by D1 receptors stimulates CREB and ∆FosB
expression. These molecules are increased in response to chronic cocaine and can
produce long lasting changes in striatal neurons associated with the drug addicted state
(Ron and Jurd, 2005). Further evidence implicating D1R signaling in mediating the long
term changes associated with psychostimulant use is the finding that increases in spine
density occurring with chronic cocaine use are selectively stable in D1R but not in D2Rexpressing nucleus accumbens neurons (Lee et al., 2006).
In addition to D1 receptors, D2Rs are also important in mediating the locomotoractivating and rewarding effects of psychostimulant drugs of abuse. Aspects of the
induction phase of cocaine-induced locomotor activity are selectively blocked by D2R
antagonists but not by non-specific motor depressant drugs (Chausmer and Katz, 2001).
Additionally, cocaine-seeking behavior is enhanced by stimulation of the nucleus
accumbens with D2 R but not D1 R agonists (Self et al., 1996). Recent studies have
shown that a regulator of G protein signaling, RGS9-2, plays an essential role in cocaineinduced hyperlocomotion and conditioned place preference. The primary target of
RGS9-2 was shown to be the D2 receptor (Rahman et al., 2003). Another study showed
that D2 receptors can interact with a subunit of the NMDA receptor, NR2B, and that this
interaction is induced by cocaine administration and required for the full induction of the
locomotor response to cocaine. Functionally, this interaction resulted in decreased
NMDA activity and inhibition of indirect pathway neurons which is associated with
increased locomotor activity (Liu et al., 2006). Together these results suggest that both
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D1 and D2 receptors are important for different aspects of the biochemical and
behavioral responses to psychostimulant drugs of abuse.

Dopamine Receptors and Schizophrenia
Abnormalities in dopamine signaling were classically linked to schizophrenia
based on the discovery that compounds with high D2 receptor antagonism were
successful in reducing the positive or psychotic symptoms of schizophrenia (Creese et al.,
1976; Seeman and Lee, 1975). Newer generation “atypical” antipsychotic drugs were
developed to target the negative symptoms and cognitive disruptions in schizophrenia
which were not resolved by classical drugs. Atypical antipsychotics are active at
different classes of serotonin and adrenergic receptors. Clinically effective doses of these
drugs, however, still retain the ability to bind striatal D2 receptors (Abi-Dargham and
Laruelle, 2005). In addition to a D2 receptor role in antipsychotic drug action, imaging
studies have demonstrated enhanced striatal D2R binding in untreated schizophrenic
patients suggesting an elevation of D2R activity in this disorder (Laruelle and
Weinberger, 2001).
Balanced D1 receptor activation has been shown to be important for optimal
performance in cognitive tasks mediated by the prefrontal cortex (PFC) (Goldman-Rakic
et al., 2000). It is thought that deficiency in PFC function is associated with the negative
and cognitive symptoms of schizophrenia. Therefore a link between D1 receptor activity
in the PFC and schizophrenia has been made. The current dopamine hypothesis of
schizophrenia states that hyperactivity of striatal D2 receptors contributes to the positive,
psychotic symptoms of schizophrenia, while hypoactivity of PFC D1 receptors underlies
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the negative and cognitive disturbances seen in this disease (Guillin et al., 2007). Along
with a strong dopaminergic component, schizophrenia has also been associated with
perturbations in other neurotransmitter systems including serotonin, glutamate, GABA
and acetycholine. Given the high level of overlap of these pathways in the BG and
limbic system, it is very likely that there are complex interactions and imbalances among
these systems which contribute to the psychopathology of schizophrenia.

Dopamine Receptor Signaling in Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the
progressive loss of dopamine due to the death of dopaminergic neurons in the SNc.
Clinically, PD is manifested by an inability to translate thought into coordinated
movement resulting in bradykinesia (slowed movement), resting tremor, and muscular
rigidity. In addition to disruptions in movement, PD is also associated with cognitive
dysfunctions which often manifest in the later stages of PD. The loss of dopaminergic
innervation of the striatum results in profound secondary adaptations in MSNs which
underlie the manifestation of PD symptoms. It is likely that imbalance in direct and
indirect pathway signaling is an important contributor to PD symptomology (Albin et al.,
1989). Due to the difficulty in studying biochemical processes selectively in direct and
indirect pathway neurons, progress has been limited in understanding the precise pattern
of dysfunction in these pathways. Recent studies, however, using BAC transgenic mouse
technology to label striatonigral and striatopallidal neurons, have shown differences in
these cell populations in response to dopamine loss. A study using transgenic mice
which express EGFP under the control of the D1R and D2R promoters, showed that
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striatal dopamine depletion induced a selective loss of glutamatergic synapses and spines
on D2R striatopallidal neurons with no change in spine structure or physiology in D1R
striatonigral neurons (Day et al., 2006). The authors suggest that the loss of D2 receptor
signaling after DA depletion results in disinhibition of synaptic calcium channels causing
destabilization of spines and synaptic contacts. This loss of glutamatergic input results in
further adaptations in striatopallidal neurons which alters their pattern of firing to GPi
neurons. Disrupted striatopallidal input results in expression of synchronous bursting
rhythms in the GPi/STN network which has been thought to underlie the expression of
PD motor symptoms, as lesions or deep-brain stimulation of these structures alleviates
these symptoms in PD patients (Chan et al., 2005).
Abnormal D1 receptor signaling has also been implicated in Parkinson’s disease,
specifically in the emergence of motor complications associated with the
pharmacological treatment of PD. L-DOPA has been the leading drug prescribed for PD
for the past 40 years owing to its ability to successfully alleviate the manifestation of PD
motor symptoms. L-DOPA is highly effective during the early stages of PD, but its
efficiency declines with sustained use and over time it can induce debilitating motor
fluctuations and complications, known as L-DOPA induced dyskinesias (Mercuri and
Bernardi, 2005). Specific alterations in D1 receptor signaling have been linked to the
expression of L-DOPA induced dyskinesias (LIDs). Although there is no change in
striatal D1 receptor expression, downstream signaling pathways of the D1 receptor
become hypersensitized during chronic L-DOPA treatment resulting in robust acute
locomotor induction in response to L-DOPA. One substrate of this sensitization is the
Gα/olf protein which is coupled to striatal D1 receptors and mediates D1R stimulation of
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cAMP production. A recent study found that membrane levels of Gα/olf were increased in
the putamen of PD patients and in 6-OHDA lesioned rats, a rodent model of PD. This
increase in Gα/olf was associated with an increase in DA-dependent adenylyl cyclase
activity (Corvol et al., 2004). Downstream signaling molecules such as ERK1/2 and the
immediate early gene c-fos also exhibit sensitized responses to L-DOPA which have been
shown to be D1 receptor mediated (Gerfen, 2003; Westin et al., 2007).
It is clear from these studies that balanced D1 and D2 receptor signaling is vital
for normal brain function. Although studies have uncovered some differential functions
of D1 and D2 receptors, studies have been limited by the lack of ability to fully
distinguish signaling selectively in D1R and D2R-expressing cell populations.
Behavioral and biochemical responses to receptor agonists and antagonists have produced
valuable information. However, the effects measured in response to these drugs reflect
an average of responses from all striatal cell types. Better tools are needed to understand
more precisely the biochemical signaling cascades mediated by different classes of
dopamine receptors in the different striatal cell types.

IV. DARPP-32
Striatal signal transduction is dependent upon the coordination of fast and slow
signaling processes. As mentioned previously, slow synaptic transmission involves a
variety of second messenger molecules, among which protein kinases and phosphatases
play a vital role. Twenty-five years ago, a phospho-protein named Dopamine- and cyclic
AMP-regulated Phosphoprotein of 32kD (DARPP-32) was discovered to be enriched in
the dopaminoceptive neurons of the striatum and to be phosphorylated in response to

30

dopamine and cAMP (Walaas et al., 1983). Since then, a variety of molecular, cellular
and functional approaches have shown that DARPP-32 is an essential mediator of the
effects of dopamine and other neurotransmitters in the striatum (Fienberg and Greengard,
2000; Svenningsson et al., 2004). DARPP-32 has the unique ability to act as a protein
kinase inhibitor or a protein phosphatase inhibitor depending on its state of
phosphorylation at four well-characterized sites (see below). Every striatal signaling
pathway mentioned in the previous sections can affect the phosphorylation of DARPP-32
at one or more sites. Studies with the DARPP-32 knock-out mouse have shown that
DARPP-32 mediates the actions of many of these molecules (Fienberg and Greengard,
2000).

Characteristics of DARPP-32
DARPP-32 is an ~200 amino acid protein which exists as a soluble elongated
monomer and has an N-terminal domain which binds protein phosphatase 1 (PP-1)
(Hemmings et al., 1984c; Hemmings et al., 1984d) (Figure 1.4). This N-terminal domain
contains two regions which are involved in the binding of DARPP-32 to PP-1. A small
domain consisting of amino acids 7-11 (KKIQF) interacts with PP-1 at a site removed
from the active site and this KKIQF docking motif is shared with other proteins that bind
PP-1, including inhibitor-1, spinophillin, and neurabin (Greengard et al., 1999). The
region surrounding the threonine 34 residue (T34) binds PP-1 at its active site preventing
access to phosphorylated substrates (Kwon et al., 1997). When DARPP-32 is
phosphorylated at T34, it is converted into a potent high-affinity inhibitor of PP-1 with an
IC50 of approximately 10-9 M (Hemmings et al., 1984a). DARPP-32 is expressed at very
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high concentrations (~50 µM) in both striatonigral and striatopallidal neurons and
therefore a substantial portion of PP-1 activity is inhibited in vivo in response to
dopaminergic stimulation (Ouimet et al., 1998). PP-1 is a major multifunctional
serine/threonine phosphatase in the brain which regulates the phosphorylation of many
downstream physiological effectors including neurotransmitter receptors and voltagegated ion channels (Greengard et al., 1999). Therefore, by regulating PP-1 function,
DARPP-32 can regulate the physiological properties of a neuron.
One of the first notable features of DARPP-32 was its high level of expression in
dopaminoceptive neurons in the brain. Robust expression of DARPP-32 is seen in the
striatum, olfactory tubercle, bed nucleus of the stria terminalis and regions of the
amygdaloid complex, all of which receive strong dopaminergic input. Moderate to weak
expression of DARPP-32 is also found in the neocortex, primarily layers II, III, and VI,
in the Purkinjie cells of the cerebellum, in several subregions of the hypothalamus, and in
specific cell types in the retina (Ouimet et al., 1984; Witkovsky et al., 2007). Within
these cells DARPP-32 immunoreactivity has been detected in cell bodies, dendrites and
axon terminals (Ouimet et al., 1984).
A hypothesis concerning the overall function of DARPP-32 in striatal signaling
was elucidated by studies of the DARPP-32 knock-out mouse, generated in 1998. These
studies showed that basal electrophysiology and locomotor behaviors were unaffected in
the knock-outs, but the biochemical, electrophysiological, gene transcriptional, and
behavioral responses to administration of a variety of agents were absent or significantly
reduced in the DARPP-32 knock-out mice (Fienberg et al., 1998). Interestingly, many of
these responses could be re-instated in the knock-out mice by increasing the doses of the
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drugs to supraphysiological levels. These observations suggest that DARPP-32 functions
as an amplifier of signaling. In response to stimulation and activation of second
messenger cascades, protein kinases directly phosphorylate target proteins. When this
activity is combined with DARPP-32-mediated inhibition of the phosphatase PP-1, high
levels of phosphorylation and activation are sustained. When DARPP-32 is absent,
inhibition of PP-1 is relieved allowing it to dephosphorylate substrates, thereby shutting
off or reducing the effects of the drug.
As mentioned above, DARPP-32 can also serve as an inhibitor of PKA activity
when it is phosphorylated at the threonine 75 site (see below) (Bibb et al., 1999). Taken
together, these findings suggest that DARPP-32 is a dual-function amplifier of signaling
in MSNs. During periods of high cAMP/PKA activity, DARPP-32 inhibits PP-1
allowing heightened phosphorylation of PKA targets. In periods of low cAMP/PKA
activity, DARPP-32 further dampens PKA activity and allows dephosphorylation of
targets by PP-1.
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Figure 1.4 DARPP-32 Phosphorylation Sites
Schematic of DARPP-32 protein showing the location of the four known phosphorylation sites. The
kinases (upper row) and phosphatases (lower row) regulating these sites are shown. Green arrows
represent facilitatory interactions while red arrows indicate inhibitory interactions. Adapted from
(Svenningsson et al., 2004).

Biochemistry of DARPP-32 Phosphorylation
The function of DARPP-32 depends on the relative phosphorylation level of four
well characterized residues (Figure 1.4). DARPP-32 is phosphorylated by PKA at T34 in
response to dopamine acting via D1 receptors and in response to other cAMP-activating
molecules (Nishi et al., 1997). As mentioned previously, T34 phosphorylation turns
DARPP-32 into a potent inhibitor of PP-1 activity. Phospho-T34 levels are maintained at
a low basal state but can be strongly increased in response to activation of the
cAMP/PKA pathway (Nishi et al., 1999). In addition to phosphorylation by PKA, T34 is
also a good substrate for protein kinase G (PKG) (Hemmings et al., 1984d). In striatal
slices, Thr 34 is primarily dephosphorylated by the calcium activated protein phosphatase
calcineurin (also known as PP-2B) but can also be dephosphorylated by the phosphatase
PP-2A (Nishi et al., 1999).
34

Phosphorylation at serine 97 (S102 in the rat) or serine 130 in the rat (S137 in the
rat) modulates the likelihood of phosphorylation at T34. S97 is phosphorylated by casein
kinase 2 (CK2) and in vitro, S97 phosphorylation increases the efficiency of T34
phosphorylation by PKA but not PKG (Girault et al., 1989). In vitro studies have shown
that S97 is most efficiently dephosphorylated by PP-2A although PP-1 also shows
activity at this site (Girault et al., 1989). S137 is phosphorylated by casein kinase 1
(CK1) and increases T34 phosphorylation by decreasing the rate of dephosphorylation of
this site by PP-2B (Desdouits et al., 1995). In vitro and in intact cells, S130 is
preferentially dephosphorylated by PP-2C (Desdouits et al., 1998).
In contrast to T34 phosphorylation, phosphorylation at T75 has been shown to
inhibit PKA activity both towards DARPP-32 and towards other PKA substrates (Bibb et
al., 1999). T75 is phosphorylated by cyclin-dependent kinase 5 (cdk5) which is highly
expressed in the striatum and activated by the noncyclin co-factor p35. T75 is
dephosphorylated by PP-2A and distinct isoforms of this enzyme are activated in
response to both calcium signaling via AMPA and NMDA receptors, and PKA signaling
stimulated by D1 receptor activation (Ahn et al., 2007a; Ahn et al., 2007b).

Factors affecting phosphorylation of DARPP-32
As mentioned previously, the striatum receives rich innervation from a variety of
neurotransmitters and neuromodulators. All of these factors can affect the
phosphorylation of DARPP-32 at one or more sites (Table 1). Here I will discuss the
changes in DARPP-32 phosphorylation that occur in response to the striatal signaling
molecules dopamine, serotonin, adenosine, GABA and glutamate.
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Dopamine and DARPP-32. Studies have shown that dopamine acts in a
bidirectional manner whereby it exerts stimulatory biochemical effects via D1 receptors
and inhibitory biochemical effects via D2 receptors (Gerfen et al., 1990; West and Grace,
2002). This opposing action of D1 and D2 receptor stimulation is also true for the
regulation of DARPP-32 phosphorylation. Studies in vivo and in striatal slices have
shown that dopamine action via D1 R stimulates the cAMP/PKA cascade and increases
phosphorylation at T34. This pathway also dephosphorylates T75 via a PKA stimulated
increase in PP-2A activity (Ahn et al., 2007a). D2 receptor activation, conversely, results
in a decrease in T34 phosphorylation and an increase in T75 phosphorylation which are
mediated by two signaling pathways. One pathway involves the Gi mediated inhibition
of AC/cAMP signaling which decreases PKA and PP-2A activity and the other is via a
D2 R mediated increase in intracellular calcium which activates PP-2B, resulting in
dephosphorylation of T34 (Nishi et al., 1997). This opposing regulation of T34 and T75
phosphorylation results in feedback loops in each cell type whereby DARPP-32 amplifies
both the D1 R-mediated potentiation of PKA activity and the D2 R-mediated inhibition
of PKA signaling.
Serotonin and DARPP-32. Together with dopamine, serotonin is an important
modulator of striatal function. With regard to DARPP-32, the phosphorylation pattern
induced by serotonin in the striatum is similar to that produced by dopamine stimulation
of D1 receptors, although these pathways are largely independent (Svenningsson et al.,
2002a). Serotonin acting on 5-HT4 and 5-HT6 receptors increases the cAMP/PKA
cascade resulting in an increase in T34 phosphorylation and a decrease in T75
phosphorylation. An additional serotonergic pathway increases S130 phosphorylation
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due to a 5-HT2 receptor mediated increase in the PLC/CK1 pathway (Svenningsson et al.,
2002a).
Adenosine and DARPP-32. Adenosine has been shown to be an important
modulator of dopamine signaling. A2A receptors are expressed selectively in
striatopallidal neurons and stimulation of A2ARs increases the cAMP/PKA cascade
resulting in an increase in T34 phosphorylation (Svenningsson et al., 1998b). The
mechanism of action of the psychostimulant caffeine is via antagonism of A2A receptors
and this results in an increase in T75 phosphorylation due to inhibition of PP-2A
catalyzed dephosphorylation at this site (Lindskog et al., 2002).
Recently, signaling via adenosine type 1 receptors (A1R) was also shown to affect
DARPP-32 phosphorylation. In contract to A2A receptors, A1 receptors are expressed in
both direct and indirect MSNs and are coupled to Gi proteins which inhibit cAMP/PKA
signaling. A1 receptor activation in direct pathway neurons antagonizes D1R signaling
and decreases T34 phosphorylation (Yabuuchi et al., 2006). In indirect pathway neurons,
A1R stimulation is thought to have a bi-phasic response whereby T34 phosphorylation is
initially increased and then subsequently decreased. The early increase in T34
phosphorylation was attributed to pre-synaptic A1R effects on dopamine release while the
late phase was likely mediated by post-synaptic A1R inhibition of cAMP and PKA
(Yabuuchi et al., 2006).
GABA and DARPP-32. MSNs receive GABA projections from recurrent
collaterals or from striatal interneurons which can have a strong effect on membrane
potentials in these cells. In striatal slices, GABA stimulation produced a rapid increase in
the state of phosphorylation of DARPP-32 at T34. This effect was potentiated by
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forskolin, a cAMP activator, which suggests that the GABA mediated increase in T34 is
due to inhibition of PP-2B (Snyder et al., 1994). This effect is most likely mediated via
stimulation of GABAA ionotropic receptors which increase Cl- influx, decrease neuronal
excitability, and decrease calcium influx thereby inactivating PP-2B.
Glutamate and DARPP-32. Both ionotropic and metabotropic glutamate
receptors are expressed in MSNs and these receptors initiate different signaling pathways
with different temporal patterns. As a result, the regulation of DARPP-32
phosphorylation by glutamate is complex and involves at least five different signaling
cascades which operate on distinct time scales (Nishi et al., 2005).
Upon stimulation of striatal slices by glutamate, T34 phosphorylation was rapidly
increased (at 1 minute), then decreased (at 1-5 minutes), and subsequently increased at
later time points (5-10 minutes) (Nishi et al., 2005). The early increase in T34 was
shown to be dependent upon AMPA, NMDA, and GluR5 activation of intracellular
calcium which induced an increase in nitric oxide release. Nitric oxide stimulated the
cGMP and PKG pathway resulting in an increase in T34 phosphorylation. The
intermediate decrease in T34 phosphorylation was due to calcium activation of PP-2B
and dephosphorylation of this site. The increase in T34 seen at later time points was
attributed to mGluR5 signaling activating both a cAMP/PKA and a PLC/CK1 cascade.
These signaling pathways had the net effect of inhibiting dephosphorylation of T34 and
also increasing phosphorylation of S130.
The regulation of T75 phosphorylation by glutamate was also found to be
complex (Nishi et al., 2005). At intermediate (1-5 minutes) time points, T75
phosphorylation was decreased by glutamate. This decrease was due to an AMPA and
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NMDA receptor mediated increase in calcium which has been shown to activate the
B''/PR72 subunit of PP-2A resulting in dephosphorylation of T75 (Ahn et al., 2007b). At
later time points (5-10 minutes), T75 phosphorylation was increased by activation of
cdk5 which occurred via a PLC/Ca++/PP-2B/CK1 cascade (Nishi et al., 2005). This
signaling cascade has also been shown to increase phosphorylation at S130 by CK1 and
is dependent upon activation of mGluR1 receptors (Liu et al., 2001).

Table 1 Factors Affecting DARPP-32 Phosphorylation
All signaling pathways are increased in response to the factors listed, except for pathways in red which are
decreased. For details, see text. Adapted from (Svenningsson et al., 2004).
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DARPP-32 and Disorders of the Basal Ganglia
DARPP-32 and Drugs of Abuse. DARPP-32 is involved in mediating the actions
of many categories of drugs of abuse including opioids, ethanol, caffeine, cannabinoids,
and psychostimulants (Svenningsson et al., 2004). It is well established that the
dopaminergic system plays an important role in reward-related behaviors and drugs with
reinforcing properties share the ability to modulate dopamine signaling (Nestler, 2001). I
will focus here on the data implicating DARPP-32 in the acute and chronic effects of the
psychostimulant drugs, cocaine and amphetamine, which act directly on dopaminergic
neurons.
Both cocaine and amphetamine cause a robust increase in dopamine availability at
the synapse by blocking the reuptake of dopamine by pre-synaptic transporter molecules
and promoting release of dopamine from nerve terminals, respectively. This increased
dopamine binds to both D1 and D2 receptors and alters signaling in direct and indirect
pathway striatal neurons. To date there has been no method to study DARPP-32
phosphorylation independently in these cell populations. Therefore studies which are
reviewed here are based on an average of striatal signaling responses in both cell types.
Acute treatment with either cocaine or amphetamine increases phosphorylation of
T34 and decreases phosphorylation of T75 (Nishi et al., 2000). Both of these drugs cause
a robust acute induction of locomotion and this response is attenuated in the DARPP-32
knockout mouse (Fienberg et al., 1998). Psychostimulant-induced locomotion is also
reduced in mice bearing a point mutation in which T34 is replaced by the nonphosphorylatable amino acid alanine (T34A), suggesting that DARPP-32
phosphorylation at T34 is necessary for this behavioral effect (Zachariou et al., 2006).
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Chronic treatment with psychostimulants causes behavioral sensitization which is
characterized by an increased response to subsequent exposure to a drug and reflects
adaptive changes in cells responsive to these drugs. Immediate early genes such as
∆FosB, which are activated by CREB and c-fos dependent pathways, are upregulated
following chronic administration of psychostimulants (Nestler, 2001). ∆FosB regulates
the transcription of cdk5 and chronic cocaine upregulates p35, the activator of cdk5 in the
ventral striatum (Bibb et al., 2001). Likely via these pathways, chronic treatment with
cocaine is associated with an increase in DARPP-32 T75 phosphorylation and a decrease
in T34 phosphorylation (Bibb et al., 1999). It has been suggested that this may represent
a homeostatic mechanisms to counteract enhanced cAMP/PKA signaling.
In the DARPP-32 knock-out mouse, there is attenuated expression of c-fos and
∆FosB in response to chronic cocaine (Fienberg et al., 1998). DARPP-32 knock-out
mice also show reduced acquisition of cocaine self-administration and place preference,
which are indices of drugs addiction (Zachariou et al., 2006). Interestingly, T34A mutant
mice were also shown to exhibit reduced cocaine self-administration, cocaine-induced
place conditioning, locomotor sensitization, and c-fos induction (Zachariou et al., 2006;
Zhang et al., 2006). There was no change observed in these outcomes in the T75A
mutant mice suggesting that the early increase in T34 is important in setting the stage for
these latent addictive changes. In addition, S130A mutant mice shared similar
phenotypes to the T34A mice implicating S130 phosphorylation in the reinforcing effects
of cocaine (Zhang et al., 2006). These results show that psychostimulants differentially
affect DARPP-32 phosphorylation at multiple sites at different time points and that
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changes in phosphorylation at these sites are responsible for mediating many of the longterm biochemical and behavioral effects associated with chronic drug use.
DARPP-32 and Schizophrenia. Schizophrenia is a complex neurological disorder
which involves imbalances in dopamine, glutamate, serotonin and acetylcholine signaling.
The etiology and pathophysiology of schizophrenia are still unclear, however,
pharmacological interventions have proven successful in the treatment of schizophrenic
symptoms. The typical antipsychotic haloperidol has been widely used in the treatment
of schizophrenia. Haloperidol has relatively high antagonistic activity at the D2 receptor
and acute injection of haloperidol increases DARPP-32 phosphorylation at T34 (Pozzi et
al., 2003). An increase in T34 phosphorylation is also seen by administration of
eticlopride or raclopride which are selective D2 receptor antagonists (Pozzi et al., 2003).
A2A receptors are co-expressed with D2 receptors and activation of A2ARs increases
cAMP/PKA signaling while D2 receptors decrease cAMP/PKA signaling. The A2A
pathway is tonically active; therefore removal of D2 receptor inhibitory tone by
antipsychotic treatment likely shifts the balance towards increased PKA activity and T34
phosphorylation.
Stimulation of the indirect striatopallidal pathway results in an inhibition of
locomotion, an effect seen after treatment with antipsychotic drugs. High doses of
antipsychotics can also induce catalepsy which is extreme hypolocomotion characterized
by rigid immobility. In the DARPP-32 knock-out mouse, higher doses of raclopride were
required to induce catalepsy suggesting that DARPP-32 plays a role in the locomotor
effects of antipsychotics (Fienberg et al., 1998).
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D2 receptor antagonists have been shown to increase the phosphorylation of the
GluR1 subunit of the AMPA receptor at the PKA S845 site. Phosphorylation at this site
promotes glutamate transmission by increasing AMPA receptor currents and enhancing
cell surface expression of this receptor (Roche et al., 1996). This change may increase
excitability in striatopallidal neurons and contribute to the inhibitory effects of
antipsychotics on locomotor activity. This mechanism may also help counteract
overactive D2 receptor signaling which has been suggested to underlie some symptoms
of schizophrenia. The haloperidol-induced increase in GluR1 S845 phosphorylation is
abolished in both DARPP-32 knock-out mice and in T34A mutant mice (Hakansson et al.,
2006).
DARPP-32 and Parkinson’s Disease. As mentioned previously, Parkinson’s
disease is a debilitating neurodegenerative disorder caused by the death of SNc
dopaminergic neurons. This loss of dopamine causes profound imbalances and
maladaptations in both direct and indirect pathway striatal neurons. As DARPP-32 plays
an essential role in mediating dopamine signaling, there are changes in DARPP-32
phosphorylation both in the dopamine depleted and the drug treated state.
In rodents, the most common model of Parkinson’s disease is the 6hydroxydopamine (6-OHDA) lesion. 6-OHDA is a toxin which is taken up by axon
terminals expressing the dopamine transporter. 6-OHDA first causes loss of
dopaminergic axons and then subsequent loss of dopaminergic cell bodies in the SNc. A
recent study using a 6-OHDA rat model of PD showed that phosphorylation of DARPP32 at the T75 site was elevated in the dopamine depleted state while T34 phosphorylation
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was unchanged. This increase in T75 phosphorylation was maintained for up to 20
months post-lesion and was reversed with L-DOPA treatment (Brown et al., 2005).
L-DOPA is a commonly prescribed treatment for Parkinson’s disease which is
efficacious during the early stages of treatment, but is associated with debilitating motor
side-effects at later stages. L-DOPA induced dyskinesias (LIDs) are characterized by
uncontrollable abnormal movements which likely represent supersensitivity of
stimulatory locomotor pathways in the BG. One recent study showed that 6-OHDA
lesioned rats expressing high levels of LIDs did not show synaptic depotentiation to lowfrequency stimulation following induction of LTP at cortico-striatal synapses (Picconi et
al., 2003). L-DOPA treated lesioned rats which did not become dyskinetic did show
synaptic depotentiation similar to control rats suggesting that abnormal synaptic plasticity
may play a role in the dyskinesic response. In the same study it was shown that the
dyskinetic rats also had abnormally high levels of T34 phosphorylation although it was
not known which striatal cell type(s) this effect occurred in (Picconi et al., 2003).
Additionally, a recent study showed that in 6-OHDA lesioned mice treated chronically
with L-DOPA, the severity of dyskinesia was correlated with the level of T34
phosphorylation (Santini et al., 2007). Highly dyskinetic mice showed the highest levels
of T34 phosphorylation. Furthermore, DARPP-32 knock-out mice showed a significant
reduction in their dyskinetic response following chronic L-DOPA treatment (Santini et al.,
2007). As mentioned above, supersensitivity of signaling molecules downstream from
the D1 receptor have been implicated in LIDs. Since activation of D1 receptors results in
an increase in the cAMP/PKA/T34 cascade, one possibility is that the increase in
DARPP-32 T34 phosphorylation occurs mainly in D1 R striatonigral neurons.
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DARPP-32 phosphorylation: The paradox
Although much of the biochemistry of DARPP-32 phosphorylation and the
signaling cascades of many striatal neurotransmitters have been elucidated in detail, vital
questions remain in the field concerning how these various signals are processed in the
context of striatonigral and striatopallidal neurons, specifically how DARPP-32 is
regulated differently in these two cell populations. This problem is exemplified by the
major paradox that drugs such as L-DOPA and haloperidol can both increase DARPP-32
phosphorylation at T34, although these drugs have opposing behavioral and clinical
effects. Thus, L-DOPA can cause schizophrenic-like symptoms while haloperidol can
produce locomotor inhibition that resembles a Parkinson’s disease state. How then can
these drugs work through the same biochemical pathway? The straightforward solution
is that these drugs are acting via the same protein but in different neuronal cell
populations. The classical model of basal ganglia circuitry predicts that dopamine acting
on D1 receptors will increase DARPP-32 phosphorylation at T34, stimulate direct
pathway neurons, and cause an increase in locomotion. Conversely, if D2 receptor
activity is blocked, there will also be an increase in T34 phosphorylation, a stimulation of
indirect pathway neurons, and the net effect of a decrease in locomotion. If the increase
in T34 phosphorylation seen with L-DOPA is restricted to D1 R striatonigral cells and the
T34 activation seen with haloperidol treatment occurs in D2 R striatopallidal cells, then
the opposing behavioral effects of these drugs are reconciled.
Direct evidence for this cell-type specific regulation is lacking due to an inability
to distinguish phosphorylation responses in D1R-striatonigral and D2R-striatopallidal
neurons. This is due to the fact that these cells are anatomically intermixed and
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morphologically indistinguishable. In order to overcome this limitation, we have
generated novel mouse models which can distinguish DARPP-32 responses in D1 R and
D2 R-expressing neurons. These tools allow us to selectively study DARPP-32
phosphorylation in striatonigral and striatopallidal neurons in vivo as well as understand
the effects of cell-type specific deletion of DARPP-32 on behavior. These studies will be
presented in chapters three and four.
In addition to understanding the role of DARPP-32 in D1 and D2 receptor
expressing neurons, we also asked whether there are any additional residues on DARPP32 which are phosphorylated in vivo that may be relevant to DARPP-32 signaling and
function. To do this we utilized a novel mass spectrometry method developed by Dr.
Brain Chait at the Rockefeller University in combination with in vitro studies of DARPP32 phosphorylation. These studies are presented in the following chapter.
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Chapter 2
IDENTIFICATION AND CHARACTERIZATION OF NOVEL
DARPP-32 PHOSPHORYLATION SITES
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Introduction
DARPP-32 is a dual function protein which has the ability to act as a kinase
inhibitor or a phosphatase inhibitor depending on its state of phosphorylation at four
well-characterized sites, T34, T75, S97, and S130. When DARPP-32 is phosphorylated
at T34, it becomes a potent inhibitor of PP-1. When phosphorylated at T75, DARPP-32
becomes an inhibitor of PKA. The S97 and S130 sites play an important modulatory role
by facilitating phosphorylation at T34.
Analysis of the amino acid sequence of mouse DARPP-32 protein reveals that
there are 24 potential serine/threonine phosphorylation sites. To date, only four of these
are confirmed phosphorylation sites in vivo. We sought to examine whether there are
additional residues on DARPP-32 which are phosphorylated in vivo, which could play a
role in DARPP-32 signaling. To do this, we collaborated with Dr. Brian Chait and Dr.
Mi Jin of the Laboratory of Mass Spectrometry and Gaseous Ion Chemistry at The
Rockefeller University. Dr. Chait and colleagues recently established a mass
spectrometric approach which allows identification of all phosphorylated residues on a
given protein (Chang et al., 2004). We used this protocol to identify residues on DARPP32 purified from mouse striatal tissue which were basally phosphorylated in vivo.
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Results
Purification of DARPP-32 from mouse striatum
In order to look for new in vivo phosphorylation sites on DARPP-32 by mass
spectrometry, we needed picomolar amounts of highly purified DARPP-32 protein. To
do this, we devised a two step immunoprecipitation protocol which resulted in a pure
sample of DARPP-32 protein isolated from mouse striatum. We first prepared mouse
striatal tissue by focused microwave irradiation (FMI) of wild-type and DARPP-32
knock-out mice. FMI has been shown to be a superior method for preserving the
phosphorylation state of in vivo proteins as it induces rapid heat inactivation of protein
kinases, phosphatases, and proteases (O'Callaghan and Sriram, 2004). Following FMI,
dissected striata were homogenized in an acidic lysis buffer. DARPP-32 protein contains
a high number of acidic residues, which make it soluble at low pH (Hemmings et al.,
1984b). The large majority of striatal proteins are insoluble at this pH, therefore this step
resulted in removal of approximately 90% of contaminating proteins. Following the acid
extraction, DARPP-32 was immunoprecipitated using a DARPP-32 antibody which is not
phosphorylation state specific (Hemmings and Greengard, 1986).
By western blot we were able to detect a DARPP-32 positive band in
immunoprecipitated samples from wild-type but not DARPP-32 knock-out mice (Fig. 2.1,
left panel). Coomassie staining revealed the presence of protein bands at 32kD from
wild-type but not from DARPP-32 knock-out mice (Fig. 2.1, right panel). There were no
major contaminating proteins in this region. The bands seen in both panels at
approximately 50 and 25kD represent the heavy and light chains of the DARPP-32
antibody used in the immunoprecipitation.
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Figure 2.1 Immunoprecipitation of DARPP-32 from Mouse Striatum
The left panel shows detection of a DARPP-32 positive band in the immunoprecipitated sample from wildtype mouse striatum by western blot with a DARPP-32 antibody. The right panel shows a coomassie
stained gel of immunoprecipitated samples from knock-out and wild-type mice. Arrows indicates DARPP32 protein bands at 32kD. Numbers correspond to molecular weight markers, in kD. Abbreviations: WT,
wild-type; KO, DARPP-32 knock-out.

Mass Spectrometry Phosphorylation Analysis of DARPP-32
Following purification of striatal DARPP-32 protein, gel bands were digested
with trypsin and peptide fragments were analyzed for phosphorylation using the
hypothesis-driven multi-stage mass spectrometry approach (HMS-MS) (Chang et al.,
2004; Jin et al., 2005). This approach assumes that all serine and threonine residues in a
given protein can be potential phosphorylation sites. Because the level of protein
phosphorylation in vivo can be very low, phosphopeptides are often not discernable in
single stage MS. According to the HMS-MS protocol, all hypothesized phosphopeptides
are targeted for isolation and subjected to a second round of MS where phosphorylated
residues are identified by the loss of 80 or 98 Daltons (Da) in the mass spectrum,
corresponding to the mass of the H3PO4 or HPO3 molecules. Using this approach, in 6
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independent samples, seven basally phosphorylated residues were found on mouse
DARPP-32 protein. Table 2 shows a list of the phosphorylated tryptic peptides with the
phosphorylated residues indicated in blue. In addition to T34, T75, S97, and S130, three
additional sites were found to be basally phosphorylated in vivo. These were S45/46, S52,
and S192. The phosphopeptide spanning amino acids 41-56 was found as two separate
entities. Based on mass analysis, one phosphopeptide entity was shown to be
phosphorylated at one residue, either S45 or S46. Since these serines are next to each
other it could not be unambiguously determined which one was phosphorylated. The
other 41-56 phosphopeptide entity contained two phosphorylated residues which were
determined to be S52 and another site, most likely S45/S56.

Table 2 DARPP-32 Phosphopeptide Sequences
Phosphorylated residues are indicated in blue in the phosphopeptide sequence. Amino acid ranges
correspond to the amino acid numbers in the mouse DARPP-32 protein sequence. MH+P is the mass of the
peptide plus one phosphate group indicating that the peptide was phosphorylated at one residue, MH+2P is
the mass of the peptide plus two phosphates indicating that the peptide was phosphorylated at two residues.
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Quantification of phosphorylation by HMS-MS
In order to quantify changes in the phosphorylation level of the new sites in
response to drug treatments, we utilized a differential labeling technique combined with
the HMS-MS approach developed in Dr. Chait’s lab. DARPP-32 protein was purified
from mice treated with either saline or drug. The purified samples were subjected to
tryptic digestion and the resulting peptides were differentially labeled with isotopically
distinct mass tags. The tags differ in weight by 5-10Da allowing identification of the
peaks corresponding to saline or drug treated samples in the later stages of MS analysis.
The height of the phosphorylated peak in a given sample is divided by the quantity of an
unphosphorylated control peptide to normalize to total protein levels. This
phospho/dephospho ratio can be compared between saline and drug treated samples to
give a value corresponding to the amount of phosphorylation induced by the drug
treatment relative to control (Fig. 2.2a).
We used this methodology to quantify changes in phosphorylation in response to
acute injection of drugs which target the dopamine system and are known to increase the
cAMP/PKA pathway. In response to cocaine, amphetamine, or a D1 receptor agonist
(SKF81297), DARPP-32 phosphorylation at T34 was increased to 143-204% of control
levels (Fig. 2.2b). These values are consistent with previous findings (Nishi et al., 2000;
Svenningsson et al., 2003) and are also consistent with results using traditional western
blotting with a phospho-specific T34 antibody (Fig. 2.2c). When we examined the
phosphorylation pattern of two of the new sites, S45/46 and S192, we saw no significant
changes in phosphorylation with any of the drug treatments suggesting that these sites are
not regulated by the cAMP/PKA pathway. Only the S45/46 and S192 sites were
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examined in this experiment because these sites yielded phosphorylation signals high
enough for quantitative analysis.

Figure 2.2 MS Quantification of DARPP-32 Phosphorylation in Response to Dopaminergic Drugs
(a) Peaks obtained from HMS-MS analysis used to quantify T34 phosphorylation in drug treated samples.
Left peaks correspond to a dephospho-peptide used to quantify total protein levels in the sample. Right
peaks correspond to phospho-T34 peptides. Lower mass peaks (1707.9 & 1298.9) correspond to saline
treated samples, 5Da higher mass peaks correspond to drug treated samples. (b) MS quantitation of changes
in phosphorylation at T34, S45/46, and S192 in response to the drugs indicated. (c) T34 phospho-antibody
western blots corresponding to an aliquot of the samples used in (b). a & b are adapted from Fig. 6 in (Jin
et al., 2005).
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Identification of the kinases phosphorylating DARPP-32 at S45/46, S52 and S192
Since S45/46 and S192 were not regulated by PKA signaling pathways, we
sought to find the kinase(s) which can phosphorylate these sites. To do this we
performed in vitro assays whereby active kinases were added to solutions containing
recombinant DARPP-32 protein and radioactive 32P labeled ATP. Kinase activity was
measured by quantifying the incorporation of radioactive phosphate at various time
points.
We first determined the kinases which were able to phosphorylate DARPP-32 in
vitro by testing a panel of commonly expressed brain kinases (Fig. 2.3). We found that
the kinases previously known to phosphorylate DARPP-32, i.e. PKA, PKG, CKI, CKII
and cdk5, all showed moderate to high activity towards recombinant mouse DARPP-32
protein in vitro. Additionally, CamKIV and CamKII kinases also showed high activity
towards DARPP-32 in vitro. GSK-3a, MAPK, and PKC had low activity while Trk-B,
CamKI, and ROK had very little or no activity towards DARPP-32 in vitro (Fig. 2.3).
Data in Figure 2.3 provide an estimate of the relative activity of each kinase towards
DARPP-32. Because we cannot control for the overall enzymatic activity of each kinase
in vitro it is possible that a kinase with low activity in this assay, can still phosphorylate
DARPP-32 in vivo.
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Figure 2.3 In vitro Phosphorylation of DARPP-32 by Brain Kinases
Graph shows the time course of 32P labeled phosphate incorporation to recombinant DARPP-32 protein.
The Y axis is split as PKA and CamKIV had very high levels of activity compared with the other kinases.
CPM = counts per minute.

To determine whether these kinases could specifically phosphorylate the S45/46,
S52 or S192 sites, we made point mutant proteins for each of these sites in which the
serine was replaced by a non-phosphorylateable alanine residue. We then compared the
incorporation of radioactive phosphate between wild-type and mutant DARPP-32 protein
in response to the panel of active kinases. If the kinase was active at one of the new sites,
then the incorporation of 32P should be reduced in the point mutant protein. We chose to
mutate serine 45 as opposed to 46 since it had been previously reported to be
phosphorylated in vitro (Girault et al., 1989).
Out of all the kinases tested with the point mutant proteins, a significant reduction
in radioactive phosphate incorporation was seen only for CKII phosphorylation of S45A
protein (Figure 2.4a-c). At the 60 minute time point, there was a 60.7% reduction in
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phosphate incorporation in the S45A mutant protein compared to wild-type protein (Fig.
2.4b). The residual CKII phosphorylation seen in the S45A samples likely reflects CKII
phosphorylation at an additional site on DARPP-32.

Figure 2.4 CKII Phosphorylates DARPP-32 at S45
(a) Time course of 32P labeled phosphate incorporation to recombinant DARPP-32 proteins after
incubation with CKII. (b) Total radioactivity measured after 60 minutes incubation with CKII, wild-type
versus S45A mutant protein. (c) Autoradiograms comparing the intensity of 32P incorporation over-time
between wild-type and S45A mutant proteins. Abbreviations: WT, wild-type recombinant mouse DARPP32 protein; S45A, S52A, S192A, serine-to-alanine point mutant DARPP-32 protein at amino acids 45, 52,
& 192; CPM, counts per minute.
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To confirm the ability of CKII to phosphorylate S45, we submitted CKII
phosphorylated wild-type recombinant DARPP-32 to the Proteomics Resource Center at
The Rockefeller University for mass spectrometry analysis. Results confirmed that CKII
phosphorylated the S45 site as well as the S97 site. S97 was previously shown to be
phosphorylated by CKII (Girault et al., 1989). Phosphorylation at S97 likely represents
the remaining phosphorylation by CKII in the S45A mutant protein sample (Fig. 2.4). To
confirm the specificity of CKII activity towards S45, we also submitted CKI
phosphorylated DARPP-32 for MS analysis. In this case, only S130 was found to be
phosphorylated which was expected based on previous reports (Desdouits et al., 1995).
Additionally, MS analysis of PKA phosphorylated DARPP-32 revealed that only the T34
site was phosphorylated in vitro by PKA. This finding is in agreement with the MS
quantification data presented in Figure 2.3 showing that drugs known to stimulate PKA
signaling have a selective effect on T34 phosphorylation with no regulation of S45 or
S192 phosphorylation.

Discussion
The data presented here show that in addition to the four known phosphorylation
sites on DARPP-32, there are three additional sites which are basally phosphorylated in
mouse striatum in vivo (Fig. 2.5). These sites were found repeatedly in independent
samples using an unbiased mass spectrometry approach. In vitro data show that the S45
site is a good substrate for CKII. A previous study examining in vitro phosphorylation of
bovine and rat DARPP-32 also identified the S45 site as a CKII target, in addition to
S102 (S102 in the rat sequence corresponds to S97 in the mouse) (Girault et al., 1989).
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In that study, it was found that the kcat for CKII stimulated phosphorylation of S102 was
5-6 times higher than for S45. Additionally, S102 was determined to be the primary site
phosphorylated in rat striatal slices based on Edman degradation analysis. Based on
those results it was concluded that S45 was not a physiologically relevant
phosphorylation site. Here we show that this site is phosphorylated in mouse striatum in
vivo and we provide additional evidence that it can be phosphorylated by CKII in vitro.
Comparison of the amino acid sequences of human, mouse, rat, and bovine DARPP-32
(Fig. 2.6) shows that S45 is conserved across all of these species and may therefore serve
an important role in DARPP-32 signaling.
The factors regulating CKII activity in the brain are largely unknown. However,
CKII has been implicated in a variety of neuronal processes including protein degradation,
neuronal survival and differentiation, ion channel function, and synaptic plasticity ((Ulery
et al., 2006). In addition to DARPP-32, CKII has been shown to phosphorylate other
proteins important in striatal signaling such as ∆FosB, PTEN, and NMDA receptors
(Lieberman and Mody, 1999; Torres and Pulido, 2001; Ulery et al., 2006). Further
studies are needed to fully understand the signaling pathways that stimulate CKII activity,
and how phosphorylation at S45 and S97 by CKII regulates DARPP-32 function.
In contrast to S45, we did not find any effect of mutation at S52 or S192 on the
ability of the kinases tested to phosphorylate DARPP-32 in vitro. Both of these serines
are followed by prolines and therefore they could be substrates for proline-directed
kinases such as cdk5 or MAPK. cdk5/p35 has previously been shown to phosphorylate
DARPP-32 at T75 in vivo (Bibb et al., 1999). In vitro, T75 is also good substrate for
other proline-directed kinases such as cdc2 and cdk1 (Bibb et al., 1999; Svenningsson et
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al., 2004). Although we did not see any major effects of S52A or S192A mutations on
the phosphorylation of DARPP-32 by cdk5, it may have been because in vitro cdk5
activity was weak compared to the other kinases known to phosphorylate DARPP-32 (Fig.
2.3). This may be due to the necessity of additional co-activators of cdk5 which were not
present in our in vitro system. It is also possible that another kinase not tested here is
responsible for phosphorylating these sites. Comparison of the DARPP-32 amino acid
sequences revealed that the S52 site is conserved across human, mouse, rat, and bovine
species while the S192 site is present only in the mouse and human sequence (Fig. 2.6).
Further studies are needed to determine the kinases and phosphatases regulating the new
sites in order to understand their potential role in DARPP-32 signaling.

Figure 2.5 Updated Schematic of DARPP-32 Phosphorylation Sites
Schematic of DARPP-32 protein showing the location of the three new phosphorylation sites in relation to
the four known sites. The kinases (upper row) and phosphatases (lower row) regulating these sites are
shown. Green arrows represent facilitatory interactions while red arrows indicate inhibitory interactions.
Adapted from (Svenningsson et al., 2004).
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Figure 2.6 Alignment of DARPP-32 Amino Acid Sequence by Species
Comparison of human, mouse, rat and bovine DARPP-32 amino acid sequences. Blue residues are
conserved across all species. Regions where the sequence differs between species are shown in red. Grey
highlighted regions show the location of the known phosphorylation sites, T34, T75, S97, and S130.
Yellow highlighted regions indicate the location of the new phospho-sites, S45, S52, and S192.
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Chapter 3
DIFFERENTIAL PHOSPHORYLATION OF DARPP-32 IN
STRIATONIGRAL AND STRIATOPALLIDAL NEURONS
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Introduction
The striatum is the main input center of the basal ganglia and receives innervation
from various sources including corticostriatal glutamatergic neurons (Kemp and Powell,
1971) and mid-brain dopaminergic neurons (Dahlstroem and Fuxe, 1964). Medium-sized
spiny neurons (MSNs) process and integrate these varied inputs and send projections to
the output nuclei of the basal ganglia via two pathways. The striatonigral pathway
projects directly to the substantia nigra pars reticulata (SNr)/entopeduncular nucleus
while the indirect striatopallidal pathway sends projections via two intermediate
structures, the globus pallidus and subthalamic nucleus (Albin et al., 1989). These two
pathways work together to modulate behavior. Imbalance or dysregulation of these
pathways can have profound physiological consequences. MSNs express high levels of
dopamine receptors, particularly type 1 and 2 receptors (D1R and D2R). Many studies
have shown that MSNs of the direct pathway preferentially express D1 receptors which
are coupled to Gs/olf proteins and positively regulate cAMP and PKA activity (Gerfen et
al., 1990). In contrast, MSNs of the indirect pathway express D2 receptors coupled to Gi
proteins which inhibit cAMP signaling (Gerfen et al., 1990).
DARPP-32 is a key regulator of signaling in both types of MSNs (Fienberg and
Greengard, 2000; Greengard et al., 1999). DARPP-32 function depends on its state of
phosphorylation at two main regulatory sites, T34 and T75 (Greengard, 2001). When
DARPP-32 is phosphorylated at T34 by PKA it becomes a potent inhibitor of PP-1,
which in turn regulates the phosphorylation state of several classes of effector proteins
including transcription factors, ionotropic receptors, and ion channels (Greengard, 2001).
PKA also phosphorylates and activates the protein phosphatase PP-2A which
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dephosphorylates DARPP-32 at T75 (Ahn et al., 2007a; Nishi et al., 2000). When
phosphorylated at T75 by cdk5, DARPP-32 becomes an inhibitor of PKA signaling and
inhibition of PP-1 is relieved (Bibb et al., 1999).
Biochemical studies have shown that a variety of therapeutic agents and drugs of
abuse can regulate DARPP-32 phosphorylation at T34 and T75 and studies utilizing mice
with point mutations of these residues show that they are necessary for mediating many
of the actions of these drugs (Hakansson et al., 2006; Santini et al., 2007; Svenningsson
et al., 2003; Zachariou et al., 2006; Zhang et al., 2006). Administration of dopamineenhancing drugs such as cocaine and the Parkinson’s disease therapeutic, L-DOPA, has
been shown to increase T34 phosphorylation. Antipsychotics such as haloperidol
antagonize dopamine signaling via D2 receptors but can also increase T34
phosphorylation to a similar degree. Despite this similar biochemical effect, dopamineenhancing drugs and antipsychotics have opposing behavioral and clinical outcomes.
Furthermore, treatment with L-DOPA can result in “schizophrenic-like” symptoms,
whereas treatment with haloperidol can mimic the locomotor suppression seen in
Parkinson’s disease and produce the movement disorder known as tardive dyskinesia.
One possible explanation for these seemingly contradictory findings is that these
drugs may selectively activate different sub-populations of striatal neurons. Cell-type
specific analysis of signal transduction in MSNs has been difficult to address due to the
anatomical and morphological homogeneity of these cells. Traditional biochemical
studies have the limitation that they examine a mixed population of cells and results
represent only an average of the signaling events in this brain region.
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To overcome these limitations and to provide a more detailed view of signaling in
striatal cells, we genetically targeted epitope-tagged DARPP-32 protein selectively to
D1R-enriched striatonigral and D2R-enriched striatopallidal neurons. Using a selective
immunoprecipitation protocol we were able to purify phosphorylated DARPP-32 protein
specifically from D1R or D2R neurons from mouse striatal tissue. We applied this
technique to analyze phosphorylation responses to several classes of drugs which target
the striatum, namely dopamine receptor agonists, psychostimulants, antipsychotics, and
L-DOPA. Our findings show that all of these drugs exhibit cell-type specific effects
which could not be revealed with conventional techniques. These results uncover
important biochemical differences between striatonigral and striatopallidal neurons and
demonstrate the advantages of using a cell-type targeted approach.

Results
Targeting striatonigral and striatopallidal MSNs
In order to study DARPP-32 phosphorylation selectively in striatonigral and
striatopallidal neurons, we generated BAC transgenic mice that express c-terminal Flag
tagged DARPP-32 and Venus fluorescent protein under the control of the drd1a (D1R)
promoter and mice which express c-terminal Myc tagged DARPP-32 and ECFP under the
control of the drd2 (D2R) promoter (Fig. 3.1a). The Internal Ribosome Entry Site
(IRES) in these constructs allows separate translation of tagged DARPP-32 and
fluorescent marker proteins from the same mRNA transcript. We chose the D1R and
D2R promoters to target striatonigral and striatopallidal cells since the levels of these
receptors have been shown to be differentially expressed in the two neuronal populations.
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In order to confirm expression of these constructs in the correct brain regions, we
performed in situ hybridization with a 35S-labeled antisense probe against GFP that
recognized both Venus and ECFP mRNA (Fig. 3.1b). Sagittal sections from the D1RDARPP-32/Flag mice showed high expression in the striatum and olfactory tubercle.
Moderate expression was seen in the deep layers of the cortex with weak expression in
the hippocampus. Sections from the D2R-DARPP-32/Myc mice showed high levels of
expression in striatum and the SNpc/ventral tegmental area (VTA) with moderate
expression in the hippocampus. The expression patterns of our constructs recapitulate the
known patterns of drd1a and drd2 expression in mouse brain confirming accurate
expression of the transgenes. At the cellular level, we found that only a subset of striatal
nuclei labeled with Nissl stain were positive for GFP mRNA in the D1R-DARPP-32/Flag
(36.7% - 188/512) and D2R-DARPP-32/Myc (41.4% - 147/355) mouse lines
respectively (Fig. 3.1b inset).
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Figure 3.1 Generation of D1R-DARPP-32/Flag and D2R-DARPP-32/Myc mice
(a) Schematic of the modified shuttle vectors used to generate D1R-DARPP-32/Flag and D2R-DARPP32/Myc mice. IRES, internal ribosome entry site; Poly A, polyadenylation sequence; Venus, Venus
fluorescent protein; ECFP, enhanced cyan fluorescent protein. (b) In situ hybridization using a 35S labeled
antisense probe against GFP which recognizes both Venus and ECFP mRNA shows the expression of the
constructs in sagittal brain sections from wild-type (WT), D1R-DARPP-32/Flag (D1), and D2R-DARPP32/Myc (D2) mice. Insets show magnification of GFP positive striatal cells labeled with silver grains
(arrows) and unlabeled cells (arrowheads) after dipping sections from (b) in emulsion.

After demonstrating targeting of the constructs to the correct brain regions, we
confirmed that the labeled striatal cells were indeed striatonigral or striatopallidal neurons.
To do this we took advantage of the fact that striatonigral and striatopallidal cells have
different projection patterns. Striatonigral neurons send projections to the SNpr while
striatopallidal neurons project more proximally to the globus pallidus. We injected
Fluoro-Gold (FG) retrograde tracer into the SNpr which is taken up by axon terminals of
striatonigral neurons and sent via retrograde transport to cell bodies in the striatum. Only
striatonigral neurons are labeled with this method since FG is unable to traverse synapses.
Correct targeting of the FG injection is shown by the overlap in immunoflourescence
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between reactive astrocytes accumulated at the injection site (red), and the SN shown by
tyrosine hydroxylase staining (green) (Fig. 3.2a).
In the striatum we examined whether the D1R-DARPP-32/Flag and D2RDARPP-32/Myc constructs were co-expressed with the FG tracer. To identify cells
which express the D1R and D2R constructs, we used a GFP antibody that recognized
Venus protein for the D1R-DARPP-32/Flag mice and a Myc antibody for the D2RDARPP-32/Myc mice. We used the Myc antibody in the D2R line because ECFP protein
was not detectable with our GFP antibody. Although mRNA for both Venus and ECFP
was present, there were very low levels of protein expression due to the weak activity of
the IRES sequence in vivo. The fact that Venus protein was detectable by indirect
fluorescence in the D1R-DARPP-32/Flag line was likely due to the higher expression
level of the D1R-targeted transcript compared to the D2R-targeted transcript (see below).
This differential expression could be due to differences in the strength of the D1R and
D2R promoters, differences in BAC copy number, or differences in insertion location
between the lines. It is also possible that the antibodies used preferentially recognized
Venus protein over ECFP.
Double immunofluorescence revealed near 100% co-localization of FG and the
GFP marker in the D1R-DARPP-32/Flag line (Fig. 3.2b) and no co-localization of FG
and Myc in the D2R-DARPP-32/Myc line (Fig. 3.2c). These results confirm that the
D1R construct was expressed in striatonigral neurons whereas the D2R construct was
excluded from these cells.
After confirming proper targeting of the D1R and D2R constructs to striatonigral
and striatopallidal cells, the D1R-DARPP-32/Flag and D2R-DARPP-32/Myc mice were
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crossed to generate double transgenic mice. Co-staining with Flag and Myc antibodies in
striatal sections from D1R/D2R-DARPP-32 mice showed that expression of the epitope
tags was restricted to different striatal cell populations (Fig. 3.2d). This further
confirmed that we targeted distinct populations of striatal neurons with these transgenic
mouse lines.
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Figure 3.2 D1R-DARPP-32/Flag and D2R-DARPP-32/Myc Construct Expression in Striatonigral
and Striatopallidal Neurons
(a) FluoroGold retrograde tracer was injected into the substantia nigra pars reticulata (SNpr) shown by the
dashed box. Double immunoflourescence (IF) shows the overlap of tyrosine hydroxylase positive SN
neurons (green) and the injection site identified by the presence of reactive astrocytes stained with GFAP
antibody (red). (b) IF staining in striatal sections shows the co-localization of Fluoro-Gold (green) and
GFP (red) in the D1R-DARPP-32/Flag mice, scale bar = 20µm. (c) There is no co-localization of FluoroGold (green) and Myc (red) in striata from the D2R-DARPP-32/Myc mice, scale bar = 20µm (d) Double
immunofluorescence staining using Flag (green) and Myc (red) antibodies in striatal sections from
D1R/D2R-DARPP-32 double transgenic mice showing absence of co-localization, scale bar = 10µm.
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Cell type-specific immunoprecipitations
Double transgenic D1R/D2R-DARPP-32 mice were used for all biochemical
experiments because they allow direct comparison of DARPP-32 phosphorylation in both
D1R and D2R-expressing neurons in response to drug treatments within the same mouse.
A schematic outline of the in vivo biochemical experiments is shown in Figure 3.3. The
success of this method relies on accurate expression of tagged DARPP-32 protein as well
as high specificity of the Flag and Myc immunoprecipitations (IP’s).

Figure 3.3 Experimental Design of in vivo Biochemical Experiments Using D1/D2-DARPP-32 Mice
One feature of this method is the ability to incubate striatal homogenates simultaneously with Myc and
Flag antibodies by differentially coupling the antibodies to magnetic beads (brown circles) and affinity gel
(pink circles), respectively. Blue circles represent Flag tags, red circles represent Myc tags. “P” indicates
phosphorylated protein.
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We first checked protein levels of tagged DARPP-32 in single transgenic mice.
Western blotting with Flag and Myc antibodies revealed positive bands in D1R-DARPP32/Flag and D2R-DARPP-32/Myc mice respectively which ran at approximately the
same molecular weight as native DARPP-32 (i.e. 32kD). There was no significant
change in total DARPP-32 levels between wild-type, D1R-DARPP-32/Flag and D2RDARPP-32/Myc mice (Fig. 3.4a). There were also no significant differences in T34 or
T75 phosphorylation between the lines (Fig. 3.4a). These results suggest that the tagged
DARPP-32 represents only a very small fraction of total DARPP-32 expressed in these
cells which is likely due to differences in the strength of the DARPP-32 promoter
compared to the D1R and D2R promoters. This difference in expression is advantageous
because by tagging a very small percentage of DARPP-32 protein in these cells, we can
study cell-specific changes in phosphorylation without perturbing the endogenous system.
After confirming expression of the tagged DARPP-32 proteins, we optimized the
IP protocols to ensure high selectivity and specificity. Figure 3.4b shows that in the
single transgenic lines, IP using the Flag antibody selectively pulled down striatal
DARPP-32 from D1R-DARPP-32/Flag mice while the Myc IP specifically pulled down
DARPP-32 from D2R-DARPP-32/Myc mice. Further IP controls revealed that in the
double D1R/D2R-DARPP-32 mice, there was no contaminating Flag tagged protein
present in the Myc IP material and there was no Myc contamination in the Flag IP sample
(Figure 3.4c). Additionally, the IP’s were highly efficient as over 90% of the Flag and
Myc tagged proteins are pulled down with this method (Fig. 3.4d).
We also compared the amount of endogenous DARPP-32 which was not pulled
down (Fig. 3.4e, lane 4) versus the tagged DARPP-32 IP’d by the Flag and Myc
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antibodies (Fig. 3.4e, lanes 2 and 3). There was 2-3 fold higher expression of Flagtagged versus Myc-tagged DARPP-32 and approximately 30-fold higher expression of
endogenous DARPP-32 compared with Flag-tagged DARPP-32. Importantly, we were
able to detect basal levels of T34 and T75 phosphorylation in both the Flag and Myc IP
samples showing that tagged DARPP-32 protein was basally phosphorylated in vivo (Fig.
3.4f).

Figure 3.4 Cell-type Specific DARPP-32 Immunoprecipitations
(a) Equal amounts of striatal homogenate from wild-type (WT), D1R-DARPP-32/Flag (D1), and D2RDARPP-32/Myc (D2) single transgenic mice were blotted with Flag, Myc, phospho-T34, phospho-T75 and
total DARPP-32 antibodies. (b) Striatal homogenates from wild-type (WT), D1R-DARPP-32/Flag (D1),
and D2R-DARPP-32/Myc (D2) mice were incubated with Flag and Myc antibodies. Equal amounts of
IP’d sample was loaded in each lane and blotted with an antibody against total DARPP-32. (c) Striatal
homogenate prepared from D1R/D2R-DARPP-32 mice was incubated with Flag and Myc antibodies and IP
eluates were blotted with either Flag or Myc antibody. Stripped membranes were re-probed with total
DARPP-32 antibody, bottom panel, showing equal loading of IP’s. (d) Striatal homogenate from
D1R/D2R-DARPP-32 mice was incubated with Flag and Myc antibodies. 5% of each IP was loaded next
to 5% of the unbound material post-IP and blotted with Flag and Myc antibodies as shown. (e) 5% of the
Flag and Myc IP’d samples from D1R/D2R-DARPP-32 mice were loaded next to 0.5% of the homogenate
before (Input) and after (Unbound) the IPs and blotted with total DARPP-32 antibody. (f) Representative
blot of the basal level of T34 and T75 phosphorylation in Flag and Myc IP’d samples from D1R/D2RDARPP-32 mice detected by phospho-specific antibodies. pT34 blot was stripped and re-probed with total
DARPP-32 antibody (bottom panel) showing equal loading.
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Biochemistry of selective D1 and D2 receptor agonists
After establishing the specificity of the IP’s and the ability to detect DARPP-32
phosphorylation in the IP’d samples, we tested whether we could observe cell-type
specific D1R and D2R agonist mediated effects on DARPP-32 phosphorylation. Drugs
were tested in acutely prepared striatal slices and in whole animals. These
complementary approaches allowed us to compare the effects of direct stimulation of
post-synaptic receptors in striatal slices versus stimulation of these receptors throughout
the brain with in vivo injections.
We first tested the effects of the D1R agonist SKF 81297 on DARPP-32
phosphorylation in striatal slices (Fig. 3.5a,b). For the slice experiments, a method was
used analogous to that described in Fig. 3.3 except slices were prepared from fresh brain
sections. Stimulation of D1 receptors has been shown to cause an increase in the
cAMP/PKA cascade which increases phosphorylation of T34 and decreases
phosphorylation of T75 (Nishi et al., 2000). In agreement with previous studies, the D1R
agonist SKF 81297 caused a significant increase in T34 phosphorylation (441.3% ±
64.6% of control, p<.01) and a small and variable decrease in T75 (87.4% ± 8.3% of
control) in total striatal homogenates (Fig. 3.5a, left panel). In D1R neurons, SKF 81297
induced a robust 12-fold increase (1220% ± 90.3% of control, p<.001) in T34
phosphorylation with a concomitant decrease in T75 phosphorylation (70.3% ± 2% of
control, p<.001) (Fig. 3.5a, middle panel). There were no significant changes in
phosphorylation at either site in D2R neurons (Fig. 3.5a, right panel).
Application of the D2R agonist quinpirole also produced effects on DARPP-32
phosphorylation which were largely cell-type specific (Fig. 3.5c,d). Activation of D2
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receptors inhibits the cAMP/PKA signaling cascade which results in a decrease in T34
phosphorylation and an increase in T75 phosphorylation (Nishi et al., 2000). As expected,
quinpirole caused a significant decrease in T34 phosphorylation (63% ± 3.7% of control,
p<.01) and an increase in T75 phosphorylation (151.6% ± 19.3% of control, p<.05) in
total striatal homogenates (Fig. 3.5c, left panel). In D2R neurons, application of
quinpirole also caused a large decrease (38.4% ± 5% of control, p<.01) in T34
phosphorylation and an increase in T75 phosphorylation (151.7% ± 14.9% of control,
p<.01) (Fig. 3.5c, right panel). In D1R neurons, there was no change in T34
phosphorylation. There was a small increase in T75 phosphorylation in D1R neurons
(122.2% ± 6% of control, p<.05) (Fig. 3.5c, middle panel) which may reflect stimulation
of some intact pre-synaptic D2 autoreceptors by quinpirole, and a consequent decrease in
dopamine release.
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Figure 3.5 Effects of D1R and D2R agonists on DARPP-32 Phosphorylation in Striatal Slices
(a,c) Bar graphs represent group averages of DARPP-32 phosphorylation from striatal slices incubated with
vehicle, SKF 81297 (10 µM, 5 min.), or quinpirole (1 µM, 10 min.). Phospho-T34 and T75 data were
normalized to total DARPP-32 levels and expressed as percent of vehicle control. The left panels represent
data from non-tagged endogenous DARPP-32 (Total Striatum), the center panels represent data from Flag
IP’d DARPP-32 (D1R Neurons), and the right panels represent data from Myc IP’d DARPP-32 (D2R
Neurons). In each experiment 6 striatal slices from 1 mouse were divided into vehicle, SKF 81297, and
quinpirole treatment groups and slices from 3 mice were pooled by treatment for the analysis of DARPP-32
phosphorylation. Data represent averages from 4-8 independent experiments. Error bars represent SEM. *,
p<.05, **, p<.01, ***, p<.001; unpaired, two-tailed student’s t-test (b,d) Representative western blots from
treated slices. T34 and T75 phospho-specific blots (top panels) were stripped and re-probed with total
DARPP-32 antibody (bottom panels). This data was generated in collaboration with Dr. Akinori Nishi and
Mahomi Kuroiwa at Kurume University, Japan.
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Based on the findings in striatal slices showing that we could identify selective
DARPP-32 phosphorylation responses in D1R and D2R neurons, we then examined celltype specific responses to drugs injected in vivo (Fig. 3.6a,b). Similar to slices, injection
of the D1R agonist SKF 81297 in vivo resulted in a significant increase in T34
phosphorylation (140% ± 11.2% of control, p<.01) with little change in T75
phosphorylation in total striatal homogenates (Fig. 3.6a, left panel). In D1R neurons,
there was a large increase in T34 phosphorylation (219% ± 19.3% of control, p<.001) but
no change in T75 phosphorylation (Fig. 3.6a, middle panel). Additionally, in contrast to
slices, there were moderate but significant increases in both T34 and T75
phosphorylation in D2R neurons in vivo (144% ± 10.7% of control, p<.05 for T34, and
148% ± 13.4% of control, p<.01 for T75, Fig. 3.6a, right panel). Because these effects
were seen in vivo and not in striatal slices, it is likely that the changes in D2R neurons
were due to stimulation of extrastriatal D1 receptors which indirectly influence the
striatum. This finding highlights the complex changes that can occur in vivo with
injection of a D1R agonist.
Injection of the D2R agonist quinpirole in vivo also resulted in changes in
DARPP-32 phosphorylation in both cell types (Fig. 3.6c,d). As seen in slices, quinpirole
significantly decreased T34 phosphorylation (67.9% ± 4.9% of control, p<.001) and
increased T75 phosphorylation (112.2% ± 4.2% of control, p<.05) in total striatal
homogenates (Fig. 3.6c, left panel). In contrast to slices, quinpirole caused a significant
decrease in T34 phosphorylation in both D1R and D2R neurons (79.4% ± 7.7% of control,
p< .05 in D1R neurons and 62.4% ± 5.6% of control, p<.01 in D2R neurons, Fig. 3.6c).
T75 phosphorylation was also increased significantly in both cell types (137.3% ± 5.4%
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of control, p<.001 in D1R neurons, and 123.9% ± 8.2% of control, p<.05 in D2R
neurons). This D2R agonist effect on D1R neurons in vivo can be explained by the fact
that there are D2 autoreceptors expressed on dopaminergic nerve terminals which
negatively regulate the release of dopamine. Decreased dopamine binding at D1
receptors would result in decreased T34 phosphorylation and increased T75
phosphorylation as found here.
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Figure 3.6 Effects of D1R and D2R Agonists on DARPP-32 Phosphorylation in vivo
(a,c) Bar graphs represent group averages of DARPP-32 phosphorylation from D1R/D2R-DARPP-32 mice
injected i.p. with vehicle, SKF 81297 (5mg/kg), or quinpirole (0.2 mg/kg) and sacrificed 15 minutes later.
Phospho-T34 and T75 data were normalized to total DARPP-32 levels expressed as percent of vehicle
control. The left panels represent data from non-tagged endogenous DARPP-32 (Total Striatum), the
center panels represent data from Flag IP’d DARPP-32 (D1R Neurons), and the right panels represent data
from Myc IP’d DARPP-32 (D2R Neurons). Each bar represents the average of 7-12 mice from 2-3
independent experiments. Error bars represent SEM. *, p<.05, **, p<.01, ***, p<.001; unpaired, twotailed student’s t-test. (b,d) Representative western blots from drug treated D1R/D2R-DARPP-32 mice.
T34 and T75 phospho-specific blots (top panels) were stripped and re-probed with total DARPP-32
antibody (bottom panels).
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Inhibition of A2A receptors affects DARPP-32 phosphorylation in D2R neurons
A2A receptors are highly expressed in the striatum and selectively localized to
striatopallidal neurons where they are co-expressed with D2 receptors (Fredholm et al.,
2005). A2A receptors positively regulate the cAMP/PKA cascade, thereby opposing D2R
signaling in these cells (Fredholm and Svenningsson, 2003). A2AR antagonists such as
caffeine have been shown to increase DARPP-32 T75 phosphorylation due to decreased
activity of the phosphatase PP-2A (Lindskog et al., 2002). In agreement with this study,
caffeine increased T75 phosphorylation in total striatal homogenates (130.1% ± 8% of
control, p<.01) with little effect on T34 phosphorylation (Fig. 3.7a, left panel). In
accordance with its selective role in striatopallidal neurons, we found that the increase in
T75 phosphorylation seen with caffeine was restricted to D2R neurons (203.5% ± 21.3%
of control, p<.001) (Fig. 3.7a, right panel).

Cocaine and haloperidol increase T34 phosphorylation in D1R and D2R neurons
respectively
To address the paradox of how psychostimulants and antipsychotics can produce
similar biochemical effects on T34 phosphorylation in samples from whole striatum, we
injected D1R/D2R-DARPP-32 mice acutely with cocaine or haloperidol. Cocaine blocks
the dopamine transporter increasing the availability of dopamine at the synapse. It is
expected that increased dopamine acting via D1 receptors would increase T34
phosphorylation and decrease T75 phosphorylation while stimulation of D2 receptors
would decrease T34 phosphorylation and increase T75 phosphorylation. All of these
effects were found in our in vivo experiment. Cocaine increased T34 phosphorylation to
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192% ± 10.5% of control, (p<.001) in D1R neurons and decreased T34 phosphorylation
to 77.5% ± 3.3% of control, (p<.01) in D2R neurons (Fig. 3.7b). Conversely, T75
phosphorylation was decreased to 65% ± 4.4% of control, (p<.001) in D1R neurons and
increased to 123.4% ± 9.3% of control, (p<.05) in D2 R neurons (Fig. 3.7b).
The typical antipsychotic drug haloperidol showed a different pattern of
phosphorylation (Fig. 3.7c). Although haloperidol induced an increase in T34
phosphorylation in the total striatal sample similar to that found with cocaine (153.2% ±
5.2% of control, p<.001, Fig. 3.7c, left panel), this increase was highly specific to D2R
cells as opposed to D1R cells (207.8% ± 22.9% of control, p<.001 in D2R cells, 106.2 ±
4.2% in D1R cells). Additionally, there was no significant regulation of T75
phosphorylation in either cell type. Typical antipsychotics such as haloperidol are known
to be strong D2R antagonists which explains the selective increase in T34
phosphorylation in D2R cells. These results clearly show that although both cocaine and
haloperidol stimulate T34 phosphorylation, these biochemical effects are restricted to
different cell populations.

“Typical” versus “atypical” antipsychotics differ in their phosphorylation profiles
Schizophrenia is a psychiatric disorder proposed to involve dysfunction in
dopaminergic, serotonergic and/or glutamatergic signaling in the cortex and basal ganglia
(Meltzer, 1999; Svenningsson et al., 2003). Classical therapeutic drugs used to treat this
disorder, termed “typical” antipsychotics, targeted the dopamine system, specifically
D2R neurons. Typical antipsychotics such as haloperidol show strong and selective
antagonism of D2 receptors. Newer compounds known as “atypical” antipsychotics
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exhibit less activity at D2 receptors and greater binding of several classes of adrenergic
and/or serotonergic receptors. Clozapine is an example of an “atypical” antipsychotic.
Despite differences in their receptor profiles, haloperidol and clozapine both increased
T34 phosphorylation in total striatal homogenates (153.2% ± 5.2% of control, p<.001 for
haloperidol and 140.7% ± 7.7% of control, p<.001 for clozapine, Fig. 3,7c,d left panels).
To better understand the effects of haloperidol and clozapine on DARPP-32
phosphorylation in D1R and D2R neurons, we compared the cell-type specific
phosphorylation profiles of these drugs after acute in vivo injection. Similar to
haloperidol treatment, clozapine treated mice showed an increase in T34 phosphorylation
in D2R neurons, although this increase was smaller than with haloperidol (158.8% ±
16.4% of control, p<.001 for clozapine, versus 207.8% ± 22.9% of control, p<.01 for
haloperidol, Fig. 3.7c,d). There were also moderate but significant increases in T75
phosphorylation in both D1R and D2R neurons with acute clozapine treatment which
were not seen with haloperidol (140% ± 3.5% of control, p<.001 in D1R neurons,
130.2% ± 5.2% of control, p<.001 in D2R neurons, Fig. 3.7d). Because this change in
T75 phosphorylation was seen in both D1R and D2R neurons, it is possible that this
effect was mediated by a signaling pathway present in both cell types (e.g. 5-HT4/6
receptors).
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Figure 3.7 Differential Regulation of DARPP-32 Phosphorylation by Psychostimulants and
Antipsychotics
D1R/D2R-DARPP-32 mice were injected i.p. with either (a) caffeine (7.5 mg/kg), (b) cocaine (20 mg/kg),
(c) haloperidol (1 mg/kg), (d) clozapine (5 mg/kg), or vehicle and sacrificed 15 minutes later. PhosphoT34 and T75 data were normalized to total DARPP-32 levels and expressed as percent of control. The left
panels represent data from non-tagged endogenous DARPP-32 (Total Striatum), the center panels represent
data from Flag IP’d DARPP-32 (D1R Neurons), and the right panels represent data from Myc IP’d
DARPP-32 (D2R Neurons). Each bar represents the average of 7-14 mice from 2-4 experiments. Error
bars represent SEM. *, p<.05, **, p<.01, ***, p<.001; unpaired, two-tailed student’s t-test.
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Chronic L-DOPA increases DARPP-32 phosphorylation selectively in D1R neurons
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder caused by
the death of dopamine neurons in the SNpc. This loss of dopaminergic input to the
striatum results in maladaptations in a variety of signaling pathways. PD is commonly
treated with the dopamine precursor L-DOPA which is effective at alleviating the motor
symptoms of PD in the early stages of the disorder. Long-term L-DOPA treatment,
however, results in debilitating dyskinesias and abnormal movements both in PD patients
and in animal models of PD. Several studies have shown that T34 phosphorylation is
selectively increased in the dyskinetic state (Picconi et al., 2003; Santini et al., 2007).
However, it is unknown which cell type(s) this effect occurs in.
In accordance with previous reports, we found that T34 phosphorylation was
increased in striatal homogenates from 6-OHDA lesioned D1R/D2R-DARPP-32 mice
treated chronically with L-DOPA (149.5% ± 11.9% of control, p<.05, Fig. 3.8c, left
panel). It has been suggested that supersensitivity of D1R-mediated signaling may
underlie the development of L-DOPA induced dyskinesia (Corvol et al., 2004; Gerfen,
2003). In support of this hypothesis we found that T34 phosphorylation was strongly
increased in D1R neurons in response to chronic L-DOPA while there was no change in
T34 phosphorylation in D2R neurons ( 334.3% ± 39% of control, p<.05 in D1R neurons,
Fig. 3.8c). Additionally, T75 phosphorylation was significantly decreased in D1R
neurons with no change in phosphorylation at this site in D2 neurons (73.5% ± 3.9% of
control, p<.01 in D1R neurons, Fig. 3.8c).
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Figure 3.8 Chronic L-DOPA Increases T34 Phosphorylation Selectively in D1R Neurons
(a) Tyrosine hydroxylase (TH) stained coronal section showing the substantia nigra (SN) and ventral
tegmental area (VTA). Arrow points to the right 6-OHDA injected side showing the selective loss of TH
stained cell bodies in the SNc 3 weeks post-lesion. (b) Western blot of striatal homogenates from 3
individual D1R/D2R-DARPP-32 mice injected unilaterally with 6-OHDA showing the loss of striatal TH
immunoreactivity on the right lesioned side with no change in total DARPP-32 protein. L = left side, sham
injection; R= right side, 6-OHDA injection. (c) Lesioned D1R/D2R-DARPP-32 mice were injected i.p.
with either saline or L-DOPA (20mg/kg)/benserazide (12mg/kg) for 11 days and sacrificed 30 minutes after
the last injection. Phospho-T34 and T75 data were normalized to total DARPP-32 levels and expressed as
percent of lesioned saline-treated control. The left panel represents data from non-tagged endogenous
DARPP-32 (Total Striatum), the center panel represents data from Flag IP’d DARPP-32 (D1R Neurons),
and the right panel represents data from Myc IP’d DARPP-32 (D2R Neurons). Error bars represent SEM.
*, p<.05, **, p<.01; unpaired, two-tailed student’s t-test. Data from b & c were generated in collaboration
with Emanuela Santini and Dr. Gilberto Fisone, Karolinska Institutet, Sweden.
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Discussion
In order to study second messenger signaling in striatonigral and striatopallidal
neurons we developed a new BAC transgenic mouse method whereby epitope tagged
protein is expressed in selective neuronal populations using cell-type specific promoters.
The efficacy of this approach relies on the specificity of the promoters to accurately drive
expression of tagged protein as well as an immunoprecipitation protocol that allows
selective purification of the protein. This method could theoretically be used to study any
protein in any cell type in vivo. We used this technique to study DARPP-32
phosphorylation selectively in D1R-striatonigral and D2R-striatopallidal neurons in
response to various agents which target this brain area. We demonstrate cell-type
specific patterns of phosphorylation for several classes of drugs which were not possible
to discern with conventional techniques.

D1R and D2R agonists: DARPP-32 phosphorylation in slices and in vivo
We first tested the effects of direct D1 and D2 receptor agonists on DARPP-32
phosphorylation in slices and in vivo to confirm the validity of our system. The results in
striatal slices largely matched our expectations and showed that we could detect changes
in DARPP-32 phosphorylation in response to a D1 or D2 receptor agonist which occurred
specifically in D1R or D2R neurons. Interestingly, when we looked at the effects of the
same drugs in vivo we found different patterns of phosphorylation. The D2R agonist,
quinpirole, caused a decrease in T34 phosphorylation and an increase in T75
phosphorylation in both D1R and D2R neurons. This can be explained by the fact that
D2 receptors are not only expressed post-synaptically on MSNs but are also expressed
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pre-synaptically as autoreceptors on the terminals of dopaminergic neurons. When these
autoreceptors are stimulated, there is a decrease in the frequency and amount of
dopamine released (Cubeddu and Hoffmann, 1982; Pothos et al., 1998; Schmitz et al.,
2002). Decreased dopamine stimulation of D1 receptors would result in decreased T34
phosphorylation and increased T75 phosphorylation in D1R neurons as seen here. The
small increase in T75 phosphorylation seen in D1R neurons in slices may reflect the
presence of some functional nerve terminals in the striatal slice preparation which are
responsive to quinpirole. In D2R neurons both in vivo and in slices, the effects of
decreased dopamine are overridden by direct activation of post-synaptic D2 receptors by
quinpirole.
There were also effects in both cell types observed with the D1R receptor agonist
SKF 81297 in vivo. In this case we observed the expected increase in T34 in D1R
neurons but we also observed significant increases in both T34 and T75 phosphorylation
in D2R neurons. Since these results were observed in vivo and not in dissociated striatal
slices, we conclude that it must have been due to stimulation of D1 receptors outside of
the striatum. In addition to the striatum, D1 receptors are expressed in the cortex,
hippocampus and amygdala all of which have projections to the striatum (Jin et al., 2001;
Voorn et al., 2004). These projections are glutamatergic and glutamate has been shown
to result in complex changes in both T34 and T75 phosphorylation in post-synaptic
striatal neurons (Nishi et al., 2005). D1 receptors are also located on striatonigral
terminals and can affect GABA release to the VTA (Cameron and Williams, 1993).
Stimulation of these receptors would decrease dopamine input and might account for the
increase in T34 phosphorylation seen in D2R neurons. This kind of regulation is not
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unprecedented as a previous study showed that a D1 agonist injected in vivo resulted in
cFos activation in both dynorphin-expressing striatonigral and enkephalin-expressing
striatopallidal neurons (Le Moine et al., 1997).

Targeting striatopallidal neurons using the A2A receptor
In addition to dopamine signaling via D1 and D2 receptors, striatal neurons also
respond to the neuromodulator adenosine. Application of the A2AR antagonist caffeine in
vivo caused a selective increase in T75 phosphorylation in D2R neurons, likely due to
inhibition of the phosphatase PP-2A. The specificity of this effect may be due to the
restricted expression of A2A receptors in the striatum compared with other brain areas and
the fact that A2ARs are selectively expressed in striatopallidal neurons. A recent study
comparing mRNA levels of active transcripts in D1R and D2R neurons found that one of
the most differentially expressed transcripts in these cells was the A2A receptor which
showed robust enrichment in D2R striatonigral neurons (Heiman et al., 2007). For these
reasons, A2A receptors may be a more selective target than D2Rs for modification of
striatopallidal cells. An example of this is the recent emergence of A2AR antagonists as
non-dopaminergic therapies to treat Parkinson’s disease (PD) (Schwarzschild et al., 2006).
Traditional therapies such as L-DOPA or dopamine receptor agonists target D1 and/or D2
receptors. As demonstrated here, in vivo injection of dopamine receptor agonists results
in complex changes in DARPP-32 phosphorylation in both striatonigral and
striatopallidal neurons. Added to the further array of adaptations in these pathways
associated with dopamine loss in PD, these agents may have broad effects that are
difficult to predict or control. Therefore, data presented here showing the specificity of
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A2AR antagonists in vivo support the idea that A2A receptors may provide a more
selective target for modification of striatopallidal neurons which could be beneficial in
PD.

The opposing effects of cocaine on striatonigral and striatopallidal neurons
The benefit of using a cell-type targeted approach to study DARPP-32
phosphorylation is exemplified by the results obtained with cocaine. Cocaine caused a
robust increase in T34 phosphorylation in D1R neurons and a decrease in T34
phosphorylation in D2R neurons. Since the increase in T34 phosphorylation in D1R
neurons was larger than the decrease in D2R neurons, the total striatal sample showed a
moderate increase in T34 phosphorylation reflecting an averaging of these two effects.
The same is true for T75 phosphorylation whereby cocaine treatment resulted in opposing
changes in D1R and D2R neurons, and data obtained in the total striatal sample was an
average of these effects. This differential regulation of striatonigral and striatopallidal
neurons by cocaine is important, however, as it reveals how dopamine can modulate both
striatal output pathways in a way that results in a synergistic effect on the basal ganglia’s
control of motor function.
Activation of the D1R striatonigral pathway results in disinhibition of
thalamocortical neurons and increased motor activity, whereas activation of the D2R
striatopallidal pathway enhances the inhibition exerted by the basal ganglia and depresses
motor function (see Fig. 1.3). Cocaine increases activation of Gi-coupled D2 receptors
which decreases PKA activity and T34 phosphorylation in D2R striatopallidal neurons.
This decrease in PKA/T34 phosphorylation has the overall effect of decreased
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excitability in these cells (Yan et al., 1999). This shuts down the inhibitory activity of the
striatopallidal pathway allowing strong stimulation of motor activity by the direct
pathway, which is a hallmark cocaine response (Nestler, 2001). Thus, the study of
DARPP-32 phosphorylation in D1R and D2R neurons in response to a dopamine
potentiator, cocaine, has revealed a molecular mechanism for the synergistic actions of
striatonigral and striatopallidal neurons.

DARPP-32 phosphorylation in response to antipsychotics
In contrast to the psychostimulant cocaine, the “typical” antipsychotic haloperidol
causes behavioral sedation and catalepsy (Meltzer, 1999). Despite these opposing
behavioral effects, cocaine and haloperidol both increase T34 phosphorylation in total
striatal samples. Here we show that this increase is restricted to D1R neurons with
cocaine and to D2R neurons with haloperidol. Haloperidol is expected to act on D2R
neurons since it is a strong antagonist at D2 receptors. D2R striatopallidal neurons also
express A2A receptors which counteract D2R signaling by increasing cAMP and PKA
activity (Fredholm and Svenningsson, 2003). Haloperidol blocks the inhibitory effect of
D2 receptor activation, shifting the balance towards positive regulation of cAMP by
endogenous adenosine (Fredholm et al., 2005). This results in an increase in T34
phosphorylation in D2R neurons.
Clozapine is an example of an “atypical” antipsychotic which has little D2R
activity but has affinity for 5-HT2(a-c), 5-HT3, 5-HT6, 5-HT1a, adrenergic1 & 2, and mAch
receptors. Although haloperidol and clozapine both increased T34 phosphorylation
selectively in D2R neurons, the increase was much larger with haloperidol than with
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clozapine. Clozapine had additional effects on T75 phosphorylation which were present
in both D1R and D2R cell types. The regulation of T34 phosphorylation in D2R neurons
may represent a common mechanism of action of antipsychotics which counteracts the
overactive striatal D2R signaling associated with schizophrenia (Guillin et al., 2007).
The very high levels of T34 achieved with haloperidol may exceed the beneficial level
and reach levels associated with unwanted locomotor side effects. In agreement with this,
clinical studies show that in vivo D2R occupancy by antipsychotics exceeding 80% is
often associated with extra-pyramidal side effects (Farde et al., 1992). The more limited
increase in T34 phosphorylation balanced by increases in T75 seen with clozapine could
reflect this drug’s ability to target several different pathways which may be beneficial in
treating a disorder as complex as schizophrenia.
Striatal neurons express 5-HT2a&c, 5-HT3, 5-HT4 and 5-HT6 receptors and
DARPP-32 has been shown to mediate responses to serotonin in the striatum
(Svenningsson et al., 2002a). One possible mechanism for clozapine’s effects on T75
phosphorylation could be via antagonism of Gs-coupled striatal 5-HT4 or 5-HT6 receptors
which would decrease PKA and PP-2A activity leading to an increase in T75
phosphorylation in both cell types. Future studies could test clozapine in combination
with different receptor agonists and antagonists to determine the contribution of these
signaling pathways to the clozapine effect on DARPP-32 phosphorylation.

L-DOPA and D1 receptor supersensitivity
L-DOPA is one of the most commonly prescribed drugs used in the treatment of
Parkinson’s disease. However, treatment with L-DOPA does not fully mimic the

90

endogenous physiological pattern of dopamine stimulation (Chase and Oh, 2000). This
long-term non-physiological stimulation of DA receptors combined with secondary
adaptations due to decreasing endogenous dopamine is thought to result in the expression
of motor fluctuations and abnormal movements known as dyskinesias (Chase and Oh,
2000). It has been suggested that selective hypersensitivity of the D1R striatonigral
pathway might account for these motor symptoms. Several studies have shown that
signaling molecules downstream of the D1R are sensitized after chronic treatment with
L-DOPA which could result in overactivity of the direct pathway (Aubert et al., 2005;
Corvol et al., 2004; Gerfen, 2003).
It has also been shown that there is an increase in DARPP-32 phosphorylation at
T34 which is correlated with the severity of dyskinesia (Santini et al., 2007). We show
here that the increase in T34 phosphorylation seen with chronic L-DOPA treatment is
restricted to D1R striatonigral neurons. In addition to the increase in T34
phosphorylation, we also observed a significant decrease in T75 phosphorylation
selective to D1R neurons. This pattern of DARPP-32 phosphorylation amplifies PKA
signaling whereby increased T34 phosphorylation inhibits the dephosphorylation of
down-stream targets by PP-1 and decreased T75 phosphorylation relieves any inhibition
of PKA signaling by DARPP-32 (Nishi et al., 2000). An amplification of PKA signaling
in response to L-DOPA is supported by the finding that PKA/PP-1 targets such as AMPA
receptors and mitogen-activated protein kinase/ERK kinase (MEK) also show increased
phosphorylation in response to L-DOPA (Santini et al., 2007). The fact that L-DOPA
produced robust changes in DARPP-32 phosphorylation in D1R cells with no effect on
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D2R cells supports the hypothesis that D1 receptor signaling pathways are selectively
prone to sensitization resulting from chronic L-DOPA treatment.

Conclusions
In addition to the drugs tested here, there are a variety of additional agents which
have been shown to regulate DARPP-32 phosphorylation in striatal neurons (see Table 1).
For many of these factors it is unclear whether they equally target both D1R and D2R
neurons, or whether they have cell-type specific effects. We expect that further studies
utilizing the cell-type targeted approach presented in this chapter will be important in
gaining more detailed insights into striatal signaling.
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Chapter 4
BEHAVIORAL ANALYSIS OF CONDITIONAL DARPP-32 KNOCK-OUT MICE
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Introduction
Medium spiny neurons (MSNs) of the striatum receive and process input from a
variety of sources including glutamate from the cortex and dopamine from the mid-brain.
MSNs project from the dorsal striatum to the output nuclei of the basal ganglia via two
pathways. The direct striatonigral pathway sends GABA-ergic projections to the
GPi/SNr which in turn projects back to the cortex by way of the thalamus. The indirect
striatopallidal pathway sends GABA-ergic projections to the GPe which then projects to
the STN which in turn innervates the GPi/SNr. Stimulation of the direct pathway has the
net effect of stimulating locomotion while excitation of the indirect pathway suppresses
locomotor activity. Dopamine exerts opposing effects on these pathways; it stimulates
the direct pathway and inhibits the indirect pathway. This opposing regulation is due to
the presence of different sub-classes of dopamine receptors on direct and indirect
pathway neurons. Direct pathway striatonigral neurons preferentially express type 1
dopamine receptors (D1R) which upon stimulation by dopamine positively regulate the
cAMP/PKA/DARPP-32 T34 cascade. Indirect striatopallidal neurons express type 2
dopamine receptors (D2R) which couple to Gi proteins and negatively regulate the
cAMP/PKA/DARPP-32 T34 signaling pathway.
In the previous chapter it was shown that agents which cause an increase in
locomotion, i.e. cocaine and L-DOPA, increase the phosphorylation of DARPP-32 at T34
selectively in D1R-expressing direct pathway striatal neurons. Conversely,
antipsychotics such as haloperidol and clozapine increase T34 phosphorylation
specifically in D2R-expressing indirect pathway striatal neurons. Increased T34
phosphorylation amplifies PKA signaling by inhibiting the dephosphorylation of PKA
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targets by protein phosphatase 1. Enhanced PKA activity is associated with an increase
in excitability in MSNs due in part to its ability to phosphorylate glutamate receptors,
which positively regulates receptor activity. Through this mechanism, T34
phosphorylation can be viewed as a biochemical marker for the relative activation state of
striatonigral and striatopallidal neurons. Inhibition of T34 phosphorylation in either celltype should therefore result in a decrease in excitability in that cell-type and a decrease in
the behavioral effect mediated by the corresponding pathway.
To directly test this hypothesis, we generated conditional knock-out mice in
which DARPP-32 protein was selectively deleted in either direct or indirect pathway
striatal neurons. To achieve a conditional cell-type specific deletion we utilized the CreLoxP system. We chose the D1R and D2R promoters to drive Cre recombinase
expression as we have shown previously that these promoters selectively target direct and
indirect pathway neurons respectively. We studied these mice to examine the relative
contribution of the direct and indirect pathways to basal open field locomotor behavior as
well as drug induced locomotor activity.

Results
Generation of conditional DARPP-32 knock-out mice
In order to generate a conditional knock-out (cKO) of DARPP-32, we made a
mouse line in which exons 1-4 of the DARPP-32 gene were flanked by loxP sites (floxed
DARPP-32 mice) (Fig. 4.1a). Through homologous recombination, the floxed DARPP32 gene was inserted into the endogenous DARPP-32 gene locus. The presence of floxed
versus wild-type alleles was identified by PCR genotyping using primers in which the
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presence of the wild-type allele resulted in a 376bp band and the floxed allele gave a
486bp band (Fig. 4.1b). The introduction of the loxP sites into the mouse DARPP-32
gene had no effect on the expression of DARPP-32 protein in the striatum of floxedDARPP-32 mice (Fig. 4.1c).
After confirming normal expression of striatal DARPP-32 protein in the
homozygous floxed DARPP-32 mice, we bred these mice to D1R-Cre and D2R-Cre BAC
mice generated by the GENSAT project. The expression of Cre recombinase in these
BAC mice has previously been characterized (Gong et al., 2007a). The D1R-Cre line
shows high levels of expression in the striatum, specifically in neurons which project to
the SNr. There is also Cre expression distributed in other regions consistent with the
known pattern of endogenous drd1a gene expression. The D2R-Cre line used here was
the ER44 line which shows expression of Cre in striatal neurons projecting to the GPe, as
well as in additional regions known to express the drd2 gene, such as the SNc.
To determine the presence of D1R- or D2R-driven Cre expression in our cKO
DARPP-32 mice, we generated PCR primers in which the 5’ primer sequence was
located in the D1 or D2 receptor promoter and the 3’ primer sequence was in the Cre
recombinase gene. Figure 4.1d shows a schematic of the location of these primers in the
D1R-Cre and D2R-Cre transgenes, and figure 4.1e shows the detection of D1R- or D2Rdriven Cre in the cKO DARPP-32 mice using PCR genotyping.
The D1R-Cre and D2R-Cre mice were made on an FVB genetic background,
while the floxed DARPP-32 mice were made on a C57/Bl6 genetic background. Since
the background strain of knock-out mice has been shown to impact their behavioral
responses (Kelly et al., 1998), we used the following breeding strategy to generate cKO
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DARPP-32 mice. Homozygous floxed-DARPP-32 C57/Bl6 mice were first bred to either
D1R-Cre or D2R-Cre FVB mice. The heterozygous floxed-DARPP-32 D1R- or D2RCre positive offspring were then bred back to homozygous floxed-DARPP-32 C57/Bl6
mice. We selected homozygous floxed-DARPP-32 D1R- or D2R-Cre positive offspring
to breed again to the homozygous floxed-DARPP-32 C57/Bl6 mice. Using this type of
cross, subsequent generations were all homozygous floxed and either positive or negative
for D1R- or D2R-Cre. With this breeding strategy, the mice were continually
backcrossed to the C57/Bl6 background and littermate controls could be used for all
behavioral analysis. Mice negative for Cre were considered wild-types (WT) while mice
positive for Cre were considered conditional knock-outs (D1R-D32-KO or D2R-D32KO).

Expression of DARPP-32 protein in D1R-D32-KO and D2R-D32-KO mice
We determined the efficiency of Cre-mediated deletion of DARPP-32 by
examining striatal DARPP-32 protein levels by western blotting (Fig. 4.1f). There was a
69.8% ± 3.3% (p<.001) reduction in total DARPP-32 protein in the D1R-D32-KO mice
and a 41.3% ± 6.1% (p,<.001) reduction in DARPP-32 in the D2R-D32-KO mice (Fig.
4.1g). The residual DARPP-32 expression in the conditional knock-out mice reflects
intact DARPP-32 protein expression in the other cell type (see Fig. 4.2 below).
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Figure 4.1 Generation of Conditional DARPP-32 Knock-out Mice
(a) Schematic showing targeting of the DARPP-32 gene. Blue boxes represent exons, red triangles show
the position of the loxP sites flanking exons 1-4. Black arrows indicate the location of the genotyping
primers used in the PCR shown in (b). (b) Genotype PCR from floxed DARPP-32 mice revealing a 376bp
wild-type (WT) band and a 486bp Floxed band. (c) Western blot showing normal expression levels of
DARPP-32 protein in striata from floxed DARPP-32 mice with genotypes indicated. (d) Schematic of the
D1R- and D2R-Cre BAC transgenes. Colored arrows indicate the position of primers used for genotyping
in (e). (e) Genotype PCR from conditional knock-out mice using D1R-Cre and D2R-Cre primers to
selectively identify Cre expression in D1R and D2R cells. Double knock-out (KO) mice were generated by
breeding D1R-D32-KO mice with D2R-D32-KO mice. (f) Western blot of striata from wild-type and cKO
DARPP-32 mice comparing protein levels of phospho-T34, phospho-T75, and total DARPP-32. Actin
antibody (bottom panel) was used to show equal loading. (g) DARPP-32 protein levels were quantified and
compared between the cKO DARPP-32 mouse lines. Optical density was measured from total DARPP-32
western blots and averages of 12 mice from each genotype were expressed as percent of wild-type protein
level. Error bars represent SEM. ***, p<.001; unpaired, two-tailed, student’s t-test.
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To further confirm the cell-type specific deletion of DARPP-32 in the conditional
knock-out mice, we examined expression of DARPP-32 protein in striatal cells using
immunofluorescence (Fig. 4.2). As expected based on previous reports, 93.2% (165/177)
of striatal neurons, identified by staining with the neuronal marker NeuN, were positive
for DARPP-32 in wild-type mice (Fig. 4.2a). In the D1R-D32-KO mice, only 34.2%
(122/357) of striatal neurons were positive for DARPP-32 (Fig. 4.2b). In the D2R-D32KO mice, 55.8% (106/190) of striatal neurons were positive for DARPP-32 (Fig. 4.2c).
The D1R-D32-KO mice were crossed with the D2R-D32-KO mice to generate double
D1R/D2R-D32-KO mice. Striatal sections from these mice showed no striatal DARPP32 immunoreactivity indicating that the neurons absent for DARPP-32 in the D1R and
D2R conditional knock-out mice were segregated to different striatal cell populations
(Fig. 4.2d).
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Figure 4.2 DARPP-32 Protein Expression in Conditional Knock-out Mice
Immunohistochemistry showing localization of the neuronal marker NeuN (red) and DARPP-32 (green) in
striatal sections. (a) Striatal sections from a wild-type mouse (b) Striatal sections from a D1R-D32-KO
mouse (c) Striatal sections from a D2R-D32-KO mouse (d) Striatal sections from a double knock-out
mouse generated by breeding D1R-D32-KO and D2R-D32-KO mice together.
Scale bars represent 20µm.
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Basal locomotor activity in conditional DARPP-32 KO mice
After confirming the selective knock-out of DARPP-32 protein in striatal D1R
and D2R neurons, we studied the basal locomotor activity of the conditional knock-out
mice. We measured the distance traveled by these mice in the open field over a period of
60 minutes. The time course of basal locomotor activity is shown in Figure 4.3a&c.
D1R-D32-KO mice exhibited reduced activity compared to wild-type littermates at all
times points (Fig. 4.3a). Conversely, D2R-D32-KO mice exhibited significantly
increased locomotor activity compared to wild-type littermates at all time points (Fig.
4.3c). Quantification of the total distance traveled in 60 minutes revealed that D1R-D32KO mice exhibited a 20% (p<.01) reduction in locomotor activity while D2R-D32-KO
mice showed a 42.2% (p<.001) increase in activity compared to wild-type mice (Fig.
4.3b,d).
To rule out the possibility of major physiological changes in the knock-out mice
which might account for the observed changes in locomotor activity, we compared the
body weights of the wild-type and cKO mice at 8 weeks of age. There was no difference
in the average weight of cKO male or female mice compared to wild-type littermates in
either line (Table 3). This suggests that the locomotor phenotype in the cKO mice was
not due to major changes in appetitive behavior or overall health.

Table 3 Body Weights of Conditional DARPP-32 Knock-out Mice

101

Figure 4.3 Basal Locomotor Activity in D1R-D32-KO and D2R-D32-KO Mice
Locomotor activity was measured by placing mice in an open field chamber and recording the distance
traveled using an overhead camera and EthoVision software. (a,c) Line graphs show the distance traveled
over a 60 minute period by wild-type and conditional knock-out mice, reported in centimeters. Each point
represents the total distance traveled during each 3 minute time interval. (a) The light blue line corresponds
to D1R-D32 wild-type mice (n=22), the dark blue line corresponds to D1R-D32-KO mice (n=16). (c) The
pale red line corresponds to D2R-D32 wild-type mice (n=17), the dark red line corresponds to D2R-D32KO mice (n=25). (b,d) Bar graphs show the average distance traveled over the entire 60 minute test period
by mice from each genotype. Error bars represent SEM. **, p<.01; ***, p<.001; unpaired, two-tailed
student’s t-test.
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Behavioral responses to acute cocaine and haloperidol in conditional DARPP-32
knock-out mice
After establishing the presence of a basal locomotor phenotype in the conditional
DARPP-32 knock-out mice, we then asked whether deletion of DARPP-32 in direct or
indirect neurons would have an effect on cocaine or haloperidol mediated locomotor
behavior. As shown in the previous chapter, acute cocaine injection resulted in
differential changes in both T34 and T75 phosphorylation in D1R direct pathway and
D2R indirect pathway neurons. Previous studies have also suggested a role for both D1R
and D2R neurons in mediating behavioral responses to cocaine (Self et al., 1996; Xu et
al., 2000). In line with these findings we found that acute locomotor responses to cocaine
were altered in both the D1R-D32-KO and D2R-D32-KO mice (Fig. 4.4).
As expected, acute injection of cocaine resulted in a robust induction of
locomotor activity in wild-type mice (Fig. 4.4a-d). In D1R-D32-KO mice, this increase
was significantly reduced across all time points (Fig. 4.4a,b). We quantified the early
phase locomotor response to cocaine since the peak of DARPP-32 T34 phosphorylation
occurs at approximately 15 minutes after cocaine injection. Results revealed that
although cocaine significantly increased locomotor activity in the D1R-D32-KO mice
compared to vehicle treated D1R-D32-KO mice (p<.05), this increase was significantly
lower than the increase seen in wild-type mice (6485 ± 990cm for WT; 3555 ± 472cm for
D1R-D32-KO, p<.05, Fig. 4.4b).
In contrast to the D1R-D32-KO mice, D2R-D32-KO mice exhibited enhanced
locomotor activity in response to cocaine compared to wild-type mice (Fig. 4.4c,d). This
enhancement was most pronounced in the early response to cocaine, 15-20 minutes post-
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injection. Quantification of the response in this time period revealed a significant
difference between D2R-D32-KO mice and wild-type mice (5598 ± 771cm for WT; 7795
± 709cm for D2R-D32-KO, p<.05, Fig. 4.4d).
The antipsychotic haloperidol is a strong antagonist of D2 receptors. In previous
experiments we showed that haloperidol caused a selective increase in T34
phosphorylation in D2R-expressing neurons with no changes in DARPP-32
phosphorylation in D1R-expressing neurons. This pattern of phosphorylation is expected
to activate the indirect pathway and result in inhibition of locomotor behavior. In wildtype mice, haloperidol significantly reduced locomotor activity (Fig. 4.4a-d). In D2RD32-KO mice, however, there was a decrease in the degree of locomotor suppression
induced by haloperidol in the first 30 minutes following drug injection (Fig. 4.4c).
Quantification of the early locomotor response to haloperidol indicated that wild-type and
D2R-D32-KO mice had a significantly different response (707 ± 47cm for WT; 1842 ±
191cm for D2R-D32-KO, p<.001, Fig. 4.4d). In contrast, there was no difference
between wild-type and D1R-D32-KO mice with regard to their locomotor response to
haloperidol (1371 ± 258cm for WT; 1228 ± 283cm for D1R-D32-KO, Fig. 4.4b).
Since the vehicle-treated D2R-D32-KO mice exhibited higher locomotor activity
compared to vehicle-treated wild-type mice (2302 ± 436cm for vehicle treated WT; 3303
± 244cm for vehicle treated D2R-D32-KO, p<.05, Fig. 4.4d), we calculated the percent
decrease in locomotor activity compared to vehicle control 15 minutes following acute
haloperidol injection. We found that even accounting for the higher baseline activity, the
D2R-D32-KO mice showed a significantly reduced response to haloperidol treatment as
measured by the percent decrease in activity compared to vehicle control (30.7% ± 2% of
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control for haloperidol treated WT mice; 55.8% ± 5.8% of control for haloperidol treated
D2R-D32-KO mice, p<.001, Fig. 4.4e).
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Figure 4.4 Locomotor Responses to Acute Cocaine and Haloperidol in Conditional DARPP-32 KO
Mice
Locomotor activity was measured by placing mice in an open field chamber and recording the distance
traveled over time using an overhead camera and EthoVision software. (a,c) Line graphs show the distance
traveled over an 81 minute period by wild-type and conditional knock-out mice, reported in centimeters.
Each point represents the total distance traveled during each 3 minute time interval. Mice were injected
with either vehicle, cocaine (20mg/kg), or haloperidol (1mg/kg) at 21 minutes and locomotor activity was
recorded for 60 minutes following the drug treatments. The light blue lines correspond to vehicle injected
(a) D1R- or (c) D2R-D32 wild-type mice (n=11,6), the dark blue lines correspond to cocaine injected (a)
D1R- or (c) D2R-D32 wild-type mice (n=10,9), the grey lines correspond to haloperidol injected (a) D1Ror (c) D2R-D32 wild-type mice (n=10,6), pale red lines correspond to vehicle injected (a) D1R- or (c)
D2R-D32 knock-out mice (n=10,12), dark red lines correspond to cocaine injected (a) D1R- or (c) D2RD32 knock-out mice (n=7,10), black lines correspond to haloperidol injected (a) D1R- or (c) D2R-D32
knock-out mice (n=5,9). (b,d) Bar graphs show the sum of the distance traveled in the 15 minute period
following drug injection by mice in each genotype and treatment group. Error bars represent SEM. Blue
asterisks indicate comparisons between the group indicated and wild-type vehicle treated mice. Red
asterisks indicate comparisons between the group indicated and knock-out vehicle treated mice. Grey
asterisks indicate comparisons between the group indicated and the corresponding treatment group in wildtype mice. *, p<.05; **, p<.01; ***, p<.001; unpaired, two-tailed student’s t-test. n.s. = no significant
difference.
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Discussion
In order to better understand the role of DARPP-32 signaling in direct and
indirect pathway neurons, we generated mice in which DARPP-32 was conditionally
deleted in either D1R-expressing or D2R-expressing neurons. These mice allowed us to
directly compare the behavioral consequences of selective alteration of these pathways at
a basal level and in response to drug treatments. We chose to knock-out DARPP-32 as it
is a key mediator of signaling in both D1R and D2R medium spiny neurons (Greengard,
2001). Global deletion of DARPP-32 results in decreased cellular and behavioral
responses to a variety of therapeutic agents and drugs of abuse (Fienberg and Greengard,
2000). Interestingly, basal physiology is generally intact in DARPP-32 knock-out mice.
This makes DARPP-32 a good choice for manipulation of direct and indirect pathway
neurons as there may be fewer adaptive responses than would be seen by knocking out
another molecule in these neurons.
DARPP-32 is an amplifier of signaling in MSNs and one interpretation is that
removal of DARPP-32 in these neurons generates a “knock-down” of these cells. By
removing DARPP-32, we remove the amplifying mechanism and therefore responses to
dopamine and other stimuli are blunted. D1R-D32-KO mice for example, can be thought
of as a knock-down of the direct pathway and therefore responses to dopamine in these
mice are primarily mediated by signaling in the indirect pathway. In accordance with this
idea, we found that the basal activity of the D1R-D32-KO mice was reduced compared to
wild-type littermates. This would be expected if the D1R-expressing direct pathway
neurons are turned off upon deletion of DARPP-32. This would shift the balance towards
decreased locomotion due to stronger inhibitory signaling by intact indirect pathway
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neurons. Likewise, the enhanced basal locomotor activity seen in the D2R-D32-KO mice
can be interpreted as due to the relief of the inhibitory tone of the D2R indirect pathway
neurons allowing strong activation of locomotor pathways by direct pathway neurons.
This type of interpretation can also be used to explain the behavioral responses to
acute cocaine and haloperidol in the conditional DARPP-32 knock-out mice. The
blunted response to cocaine in the D1R-D32-KO mice suggests that DARPP-32 signaling
in D1R neurons is required for the full locomotor response to acute cocaine. The fact that
there is an increase in locomotion in response to cocaine in the D2R-D32-KO mice
corroborates the idea that deletion of DARPP-32 in these neurons results in a silencing of
the indirect pathway. Acute cocaine treatment causes a decrease in T34 phosphorylation
and PKA activity in D2R neurons which shuts down these cells and relieves inhibition by
the indirect pathway. Removal of DARPP-32 should further dampen activity in this
pathway which may explain the enhancement of cocaine induced locomotion seen in the
D2R-D32-KO mice. It would be interesting to see how deletion of DARPP-32 directly
affects the excitability or the firing rate of these neurons to see if this could be the
mechanism underlying the behavioral effects seen here.
In the case of haloperidol, we observed a decrease in the behavioral response of
the D2R-D32-KO mice compared to wild-type mice. This was expected since
haloperidol has strong affinity for the D2 receptor and we have previously shown that
acute haloperidol causes an increase in DARPP-32 T34 phosphorylation selectively in
D2R- but not D1R-expressing neurons. It has also been shown that the total DARPP-32
knock-out mice have a reduced behavioral response to another antipsychotic drug,
raclopride (Fienberg et al., 1998). We saw a reduction in the ability of acute haloperidol
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to inhibit locomotor activity in the D2R-D32-KO mice while responses in the D1R-D32KO mice were equivalent to wild-type mice. This provides further evidence that both the
biochemical and behavioral effects of haloperidol are primarily mediated by changes in
signaling in D2R-expressing indirect pathway neurons.
One interesting observation regarding the differences in the drug induced
locomotor responses in cKO mice, was that the differences between WT and cKO mice
were largest in the first 15-30 minutes following drug treatment. This supports the idea
that the function of DARPP-32 is to amplify signaling which may be most relevant in the
early phase of drug-induced signaling changes. In line with this, we have observed that
in response to drugs injected in vivo, the peak of DARPP-32 T34 phosphorylation occurs
within the first 15-30 minutes after injection. It is possible that at later time points, the
intact signaling pathways “catch-up” in the conditional DARPP-32 knock-out mice or
that other pathways are responsible for mediating the behavioral effects at later time
points.
Additionally, we reported a basal difference in locomotor activity in both the
D1R-D32-KO and D2R-D32-KO mice, however, only D2R-D32-KO mice exhibited a
basal difference in the drug treatment experiment. This may have been due to the fact
that the basal activity trial was the first exposure to the open field chamber. In the drug
treatment trial conducted a week later, the environment was no longer novel. It has been
shown that mice show increased locomotor activity and exploratory behavior in novel
environments and that individual differences in behavior can be masked after subsequent
exposures to the environment (Piazza et al., 1990). Since the phenotype in the D1R-D32KO mice was a reduction in locomotion, there may have been a “floor” effect whereby
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the difference between knock-out and wild-type mice was obscured by an overall
decrease in activity due to the second exposure to the testing chamber. Another
possibility is that the reduction in locomotor activity in D1R-D32-KO mice is a more
subtle and variable effect. A greater number of mice were used in the basal locomotor
analysis (n=22 WT mice and n=16 D1R-D32-KO mice) than in the vehicle treated
locomotor analysis (n=11WT mice and n=10 D1R-D32-KO mice). Also both male and
female mice were tested and there may be sex differences which contribute to the
variability. Future studies using a larger and more homogenous population of mice could
test the effects of these variables.
The results presented here reveal differences in the regulation of locomotor
behavior by direct and indirect pathway neurons. Despite clear predictions based on the
classical model of basal ganglia circuitry, it has been a challenge to directly show
differences in direct pathway and indirect pathway signaling due to the difficulty in
targeting these cells. Within the striatum, these cell populations are morphologically
indistinguishable and anatomically intermixed. Studies with selective dopamine receptor
agonists and antagonists have the disadvantage that these agents can have indirect effects
in the striatum resulting from expression of D1 and D2 receptors in neurons other than
MSNs (e.g. D1 receptors in the cortex and D2 autoreceptors on striatal dopaminergic
nerve terminals). Additionally, studies with receptor knock-out mice have the
disadvantage that there are often compensatory or adaptive changes which are difficult to
control. This also could be the case with the conditional DARPP-32 knock-out mice,
however it is likely that the removal of DARPP-32 has less of an impact on basal
physiology than removal of a receptor type.
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The advantage of using a cell-type specific approach is evident when comparing
our results to results obtained with the total DARPP-32 knock-out (KO) mice. In terms
of locomotor behavior, there was no change in basal activity observed in the total
DARPP-32 KO mice (Fienberg et al., 1998). Since we saw an increase in activity in the
D2R-D32-KO mice and a decrease in activity in the D1R-D32-KO mice, there would be
no net change in activity if these effects were summed, as was observed in the total
DARPP-32 KO mice.
It was reported that the total DARPP-32 KO mice exhibited reduced responses to
cocaine both biochemically and behaviorally (Fienberg et al., 1998). At low doses of
cocaine there was a significant reduction in the acute locomotor response (10 minutes
following injection) in total DARPP-32 knock-out mice; however, at a higher 20 mg/kg
dose, there was no effect of the knock-out (Fienberg et al., 1998). We tested behavioral
responses to the 20mg/kg dose, and found that D1R-D32-KO mice had a reduced
locomotor response while the D2R-D32-KO mice exhibited an enhanced response. The
sum of these effects is again zero which accounts for the lack of an observable effect in
the total DARPP-32 KO mice. By looking at the average of striatal signaling events,
important differences between the two output pathways are missed.
Taken together, these findings support the classical model of basal ganglia
circuitry showing the opposing regulation of locomotor behavior by direct and indirect
pathway neurons. These results also directly demonstrate how dopamine can modulate
both pathways in a synergistic manner to influence locomotor activity, as seen with acute
cocaine treatment. It will be interesting to examine responses of these conditional knockout mice to other factors known to affect striatal signaling and behavior. It would be
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especially valuable to look at additional behaviors such as pre-pulse inhibition in
response to antipsychotics or conditioned place preference in response to chronic cocaine
to determine the relative contributions of the two cell types to other basal gangliamediated behaviors.
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Chapter 5
CONCLUSIONS AND FUTURE DIRECTIONS
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The striatum is a site of integration for diverse neurotransmitters and
neuromodulators. These signaling molecules originate from within the basal ganglia and
from a variety of brain regions including the cortex, mid-brain, and limbic regions. This
diversity of signaling makes the striatum unique. Medium spiny neurons of the striatum
receive the majority of these inputs and send efferent projections out of the striatum to
other basal ganglia structures. MSNs express a large number of neurotransmitter
receptors and are a model system for studying the integration of fast and slow synaptic
signaling pathways. DARPP-32 is a phosphoprotein highly enriched in MSNs which has
been shown to regulate, or be regulated by, nearly all of the signaling molecules in the
striatum. Global deletion of DARPP-32 protein results in markedly reduced or abolished
biochemical, behavioral and electrophysiological responses to a variety of agents
confirming its central importance in striatal signaling.
In addition to the integration of striatal inputs, medium spiny neurons also play an
essential role in regulating the output signaling of the basal ganglia. The two types of
striatal projection neurons comprising the direct and the indirect pathways differentially
modulate the output activity of the basal ganglia. Stimulation of the direct pathway
results in an inhibition of the GPi/SNr which increases the excitation of cortical neurons
by the thalamus. Stimulation of the indirect pathway which projects via the GPe and
STN, enhances the activity of the GPi/SNr which ultimately inhibits stimulation of the
cortex. Excitation of the direct pathway stimulates locomotion while activation of the
indirect pathway inhibits locomotion. Dopamine synergistically regulates these pathways
by exciting the direct pathway and inhibiting the indirect pathway resulting in an additive
facilitatory effect on locomotion.
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Direct and indirect striatal neurons are known to differ in their expression of
several proteins including dopamine receptors and neuropeptides. A recent study using a
novel technique to profile differences in gene expression between these two cell types has
revealed hundreds of additional gene transcripts which are differentially expressed
between direct and indirect pathway neurons (Heiman et al., 2007). Despite the overall
similarity between these cells in terms of their anatomical and morphological features,
the selective differences between these neurons allow them to differentially respond to
signaling factors within the striatum. Having two different efferent pathways with
differential signaling properties allows for more options and greater flexibility in the
ability of the basal ganglia to respond to varying signaling environments.
Traditional biochemical and behavioral studies have mainly reported changes in
overall striatal signaling or function in response to different factors. While those studies
are informative, they report an average of signaling events which obscures differences in
responses between direct and indirect pathway neurons. This has presented problems in
the interpretation of data exemplified by the paradox presented in chapter 3 concerning
the regulation of DARPP-32 phosphorylation by psychostimulants and antipsychotics.
We have attempted to address these limitations by studying striatal signaling in a celltype specific manner. These studies rely on the ability to accurately target different celltypes which has been aided by the BAC transgenic mouse methodology established by
the GENSAT project (Gong et al., 2003). We have generated transgenic mice which use
cell-type specific promoters to drive expression of tagged DARPP-32 or Cre recombinase
in direct and indirect pathway neurons. This has allowed selective purification or
deletion of proteins in specific striatal populations. By using these approaches we have
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been able to study striatal signaling in more detail and have provided direct evidence
confirming several predictions based on the classical model of basal ganglia circuitry.
Figure 5.1 summarizes the circuitry of the basal ganglia with regard to the direct
and indirect pathways. This schematic can be used to visualize how biochemical changes
in striatal neurons can ultimately affect behavioral responses. In one series of
experiments presented here we studied the selective changes in DARPP-32
phosphorylation in direct and indirect pathway striatal neurons in response to various
signaling molecules. In subsequent experiments we examined the relative contributions
of the direct and indirect pathways to behavioral responses by studying mice with a
selective deletion of DARPP-32 in striatonigral or striatopallidal neurons. These studies
are integrated in the model shown in figure 5.1 which provides a framework for studying
how changes in striatal biochemistry could be translated into behavioral responses.
The utility of this model is exemplified by our results obtained with cocaine. In
D1 receptor-expressing direct pathway neurons, acute cocaine treatment increased T34
phosphorylation and decreased T75 phosphorylation. This pattern of phosphorylation is
expected to inhibit PP-1, enhance PKA signaling, and excite striatonigral neurons of the
direct pathway. Cocaine caused a concomitant decrease in T34 phosphorylation and an
increase in T75 phosphorylation in D2R neurons which has the effect of shutting down
these neurons and inhibiting the indirect pathway. The simultaneous stimulation of the
direct pathway and inhibition of the indirect pathway resulted in a robust induction of
locomotor activity in response to cocaine in wild-type mice. Selective deletion of
DARPP-32 in direct pathway neurons decreased the locomotor response to cocaine while
deletion of DARPP-32 in indirect pathway neurons enhanced this response. Using this
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model it may be possible to make testable predictions about the behavioral effects of
drugs by examining the phosphorylation pattern of DARPP-32 in direct and indirect
pathway neurons.
We have examined the initial signaling responses and the final behavioral
responses to drugs which appear to be highly correlated, at least with respect to acute
cocaine and haloperidol-mediated changes in locomotion. Thus far we have focused on
the nigrostriatal dopamine pathway which has a well known role in mediating locomotor
behavior. This dopaminergic pathway projects largely to the dorsal striatum where it is
clear that D1R and D2R-expressing neurons have segregated projections comprising the
direct and indirect pathways. The circuitry of this system is relatively well defined which
makes it feasible to correlate changes in striatal biochemistry with clear-cut behavioral
effects. However, the acute locomotor effects of psychostimulant drugs can be
dissociated from their addictive effects and it has been well established that addiction
results from changes in the VTA-nucleus accumbens reward circuitry (Kauer and
Malenka, 2007). We have not yet examined behaviors which are mediated by the
mesolimbic dopamine system which are important aspects of chronic drug use.
It has been shown that in the ventral striatum/nucleus accumbens, D1R and D2R
are largely segregated to different sub-populations of neurons, however the projections of
these neurons are more complex and overlapping than in the dorsal striatum (Lee et al.,
2006; Lu et al., 1998). In addition, other dopamine receptors such as D3R are highly
expressed in the ventral striatum which makes dopamine signaling more complex in this
area. Furthermore, the division of the nucleus accumbens into the core and shell regions
which play selective roles in different aspects of addiction and which have different
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efferent projections further increases the complexity of this region. Studies have already
demonstrated differences between D1R and D2R-expressing neurons in the nucleus
accumbens with regard to changes in spines occurring with chronic drug use (Lee et al.,
2006). It will be very interesting to study behaviors known to be indices of addiction and
reward processes in our mouse models to understand how D1R and D2R-expressing
neurons differentially contribute to these processes.

Figure 5.1 (on the following page) Striatonigral and Striatopallidal Neurons Integrate Afferent
Signals and Modulate Behavior via the Direct and Indirect Pathways
Schematic of the direct and indirect pathways highlighting the integration of diverse afferent signals by
striatonigral and striatopallidal neurons. Striatonigral neurons preferentially express type 1 dopamine
receptors while striatopallidal neurons express type 2 dopamine receptors. There are additional differences
between these neurons in the expression of adenosine, opioid, and metabotropic glutatmate receptor subtypes. All of the signaling pathways shown here can regulate DARPP-32 phosphorylation which in turn
inhibits PP-1 or PKA depending on the relative level of phosphorylation at T34 or T75. Phosphorylation at
T34 turns DARPP-32 into a potent inhibitor of PP-1 which regulates the excitability of these neurons by
modifying the state of phosphorylation of AMPA receptors, NMDA receptors, and ion channels.
Activation of direct pathway striatonigral neurons stimulates locomotor behavior whereas activation of
indirect pathway striatopallidal neurons inhibits locomotor activity. Minus signs indicate GABA-ergic
inhibitory connections and plus signs indicate glutamatergic excitatory connections. Abbreviations: GPi,
globus pallidus internal segment; SNr, substantia nigra pars reticulata; GPe, globus pallidus external
segment; STN, subthalamic nucleus.
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Future studies
In the studies presented here we have described the initial characterization of new
mouse tools which allow the study of striatal signaling in a cell-type specific manner.
We have used these tools to understand acute responses to drugs with respect to the direct
and indirect pathways. Thus far we have studied agents which have previously been well
characterized and therefore we were able to make predictions and test these using our
model systems. Our results have largely confirmed the hypothesized mechanism of
action of these drugs. It will be interesting to use these tools to look at new pathways or
signaling molecules which are less well characterized. It would also be beneficial to
study the regulation of other DARPP-32 phosphorylation sites in addition to T34 and T75,
as less is known about how these sites might be differentially regulated in the two
pathways.
Here we studied acute biochemical responses to drugs at a single time-point. It
would be informative to study these signaling changes over time to gain a better
understanding of the temporal regulation of these processes. It would be especially
interesting to use these mice to understand the adaptive biochemical changes that occur in
response to chronic drug use. Studies have shown that although acute cocaine increases
DARPP-32 phosphorylation at T34 and decreases phosphorylation at T75, chronic
cocaine use is associated with an increase in T75 phosphorylation and a decrease in T34
phosphorylation (Bibb et al., 2001; Nishi et al., 2000). It would be interesting to see what
cell-type this increase in T75 phosphorylation occurs in and when the shift in DARPP-32
signaling takes place. Additionally, further studies using the conditional DARPP-32
knock-out mice could examine behavioral responses other than locomotion such as
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conditioned place preference or behavioral sensitization to understand the relative
contributions of the two cell-types to these correlates of drug addiction.
In addition we would also like to study the long-term changes in signaling that
occur in neurodegenerative disease models such as Parkinson’s disease. It would be
informative to do a time course study after dopamine depletion and subsequent L-DOPA
treatment to understand the temporal changes in signaling and adaptations that occur over
time within the direct and indirect pathways. In the current study we have shown that the
increase in T34 phosphorylation in response to chronic exposure to L-DOPA occurs
selectively in D1 receptor-expressing direct pathway neurons. This has provided further
evidence that signaling pathways downstream of the D1 receptor become sensitized
following chronic exposure to L-DOPA. Previous studies have shown that dykinesia is
reduced in the total DARPP-32 knock-out mouse (Santini et al., 2007). It would be
interesting to test whether the expression of L-DOPA-induced dyskinesia (LID) is
reduced upon the selective loss of DARPP-32 in D1R direct pathway neurons. If this is
the case then it might point to a possible target for intervention to prevent maladaptations
in the D1R direct pathway which underlie LID.
Much remains to be understood about the direct and indirect pathways and how
they contribute to striatal signaling and behavior. Even less is known about the other
striatal cell populations such as striatal interneurons, the patch and matrix regions, and
the subregions of the ventral striatum. Additional cell-type specific promoters selective
for these compartments could be used to study responses in these cell populations. This
selective cell-type targeted approach will be essential to provide a complete
understanding of basal ganglia function in the normal and diseased states.
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MATERIALS AND METHODS

All procedures involving animals were performed in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals and were
approved by the Rockefeller University Institutional Animal Care and Use Committee.

Purification of DARPP-32 from mouse striatum
Six to eight week-old wild-type and DARPP-32 knock-out mice were sacrificed
by focused microwave irradiation (FMI) (4.0-4.5 kW for 1.35 seconds using a small
animal microwave, Muromachi Kikai, Japan). Brains were removed and bilateral striata
were quickly dissected on a cold plate and stored in liquid nitrogen or at -80˚C until
processing. Striata from 2-3 wild-type or knock-out mice were pooled and sonicated in
sodium citrate buffer (10mM Na2HPO4, 10mM citric acid, pH2.8, 0.2% Tween-20,
phosphatase inhibitors 1:100 – Phosphatase Inhibitor Cocktail Sets I and II, Calciochem).
Samples were centrifuged at 15,000 rpm for 15 minutes to remove insoluble material.
The supernatant was adjusted to pH 6.0 using 0.5M Na2HPO4 and 20ug of a nonphosphorylation state specific total DARPP-32 antibody was added (Hemmings and
Greengard, 1986). Samples were rotated at 4˚C for 1 hour and 200µL of protein G
magnetic beads (Dynal Biotech) were added for an additional hour. Bound protein was
isolated using a magnetic particle concentrator (Dynal Biotech), washed three times in 1x
PBS, and eluted by boiling in 2x NuPAGE sample buffer. Ten percent of the final
immunoprecipitated sample was run on an SDS-PAGE gel and analyzed by western
blotting (see procedure below) using a phospho-specific polyclonal T34 antibody
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(Valjent et al., 2005). The remaining sample was reduced with 10mM DTT at 70˚C for
10 min. and then alkylated with 50mM iodoacetamide at room temperature in the dark for
30 min. Samples were separated on an SDS-PAGE gel and stained with GelCode blue
coomaassie staining reagent (Pierce).
For quantitative mass spectrometry analysis of DARPP-32 phosphorylation in
drug treated samples, wild-type C57Bl/6 mice were injected with saline, cocaine
(30mg/kg, Sigma), amphetamine (7.5mg/kg, Sigma), or SKF 81297 (5mg/kg, Tocris) and
sacrificed by FMI 15 minutes later. Brains were removed and striata were rapidly
dissected and processed using the acid extraction/immunoprecipitation protocol described
above.

Mass spectrometry analysis of DARPP-32 phosphorylation
Analysis of DARPP-32 phosphorylation by mass spectrometry using the HMSMS approach was performed as previously described (Chang et al., 2004; Jin et al., 2005).
Following SDS-PAGE of immunoprecipitated DARPP-32 samples and staining of the gel
with GelCode blue reagent (Pierce), bands corresponding to DARPP-32 were excised
from the gel. Protein in the gel band was oxidized with 0.01% performic acid reagent in
acetonitrile/water (1:1) for 15 min. at room temperature, destained in acetonitrile/50 mM
NH3HCO3 (1:1) and dried. Trypsin (250ng) in 50 mM NH4HCO3 was added, and the
digestion was allowed to proceed for 6 hours at 37˚C. For quantitative analysis of
DARPP-32 phosphorylation in drug treated samples, propionylation and peptide
extraction was achieved by sequentially treating the gel with the following solutions: (1)
50uL of 1% d0- or d10-propionic anhydride (Sigma) in acetonitrile/50mN NH4HCO3
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(1:1); (2) 30uL of 1% d0- or d10-propionic anhydride in acetonitrile; (3) twice with 50uL
of 0.1% TFA in acetonitrile/water (1:1); (4) 30uL of acetonitrile. The samples were
sonicated for 15 min. in each solution, and the supernatant from each extraction step was
combined and dried in a Speedvac.
Single-stage and MS/MS mass spectra were collected on a MALDI-QqTOF mass
spectrometer and MALDI-ion trap mass spectrometer, respectively, both fitted with
custom made ion sources (Krutchinsky et al., 2001; Krutchinsky et al., 2000). The
MALDI matrix used was 2,5-dihydroxybenzoic acid (DHB) (Sigma). MS/MS spectra
were collected for 0.5-2 min., using injection times of 100-1000ms, activation time of
300ms, and relative collision energy of 30-40%. The isolation width was 15-20 m/z units,
where the range was set to include all isotope peaks of the hypothesized phospho-peptide
pair of interest.

Generation of recombinant DARPP-32 protein and serine-to-alanine point mutant
proteins
C-terminal 6xHis tagged mouse DARPP-32 cDNA was generated by PCR using
a 6xHis tag reverse primer from a plasmid template containing mouse DARPP-32 cDNA.
After verifying the correct DNA sequence, 6xHis tagged DARPP-32 was cloned into the
pET-3a (Novagen) vector and transformed into BL21 (DE3) pLys E. coli (Novagen) for
protein expression. Transformed cultures were grown at 37˚C until they reached an
optical density of 0.6. Cultures were induced with 1mM IPTG and incubated at 37˚C for
an additional 4 hours. Cultures were spun down at 6000 rpm for 15 minutes and
resuspended in cold buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole).
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Bacterial homogenates were lysed using a french press and lysates were centrifuged at
45,000 rpm for 45 minutes at 4˚C. Supernatants were applied to an Ni-HiTrap FPLC
column (Amersham Biosciences) washed, and bound protein was eluted by using a linear
gradient starting with 100% Buffer A (300mM NaCl, 50 mM NaH2PO4, 20mM
imidazole) and ending with 100% Buffer B (300mM NaCl, 50mM NaH2PO4, 200mM
imidazole). Protein content of the eluted fractions was analyzed by SDS-PAGE followed
by coommassie staining of the gel with GelCode blue reagent (Pierce). Fractions
containing the largest amount of protein at 32kD (corresponding to DARPP-32) with the
least amount of contaminating protein were pooled, concentrated to 1-2mg/mL and stored
at -80˚C until use.
Serine-to-alanine point mutant proteins for the S45, S52, and S192 residues were
generated from the 6xHis tagged mouse DARPP-32 cDNA template using the
Quickchange Site-directed mutagenesis kit (Stratagene). Point mutations were verified
by DNA sequencing and 6xHis tagged point mutant S45A, S52A, and S192A protein was
generated and purified as described above.

In vitro kinase assays
To measure the ability of brain kinases to phosphorylate DARPP-32 protein in
vitro we added ~5ug of wild-type, S45A, S52A, or S192A recombinant protein to a 50uL
reaction mixture containing reaction buffer, ddH2O, 5uL of ATP/MgCl2 cocktail (Upstate
#20-113), 3uL kinase, and 0.5mCi of 32P ATP. Kinases, their corresponding reaction
buffers, and co-factors were obtained from the following sources: PKA, purified enzyme
previously described in (Kaczmarek et al., 1980), PKA reaction buffer (500mM HEPES,
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100mM Mg(OAc)2, 10mM EGTA final concentration); CamKIV, Upstate; CKI, New
England Biolabs; CKII, New England Biolabs and Upstate; CamKII, Upstate; PKG,
Calbiochem ; cdk5/p25, Upstate; GSK-3a, Upstate; MAPK 1 (Erk1), Upstate; p42 MAPK
(Erk2), New England Biolabs; PKC, Upstate; Trk-B, Upstate; CamKI, Upstate;
ROKα/ROCK-II, Upstate. Reactions were carried out at 30˚C and 10uL aliquots of the
reactions were removed at each time point. Reactions were stopped by boiling in 4x
sample buffer and samples were stored at -20˚C until use. Individual samples were run
out on a 10.5-14% Tris-HCL SDS-PAGE gel (Criterion, Bio-Rad), coomassie stained
with GelCode blue reagent (Pierce), and dried overnight. Dried gels were exposed to
autoradiography film and bands corresponding to DARPP-32 protein were cut out and 32P
incorporation was measured on a Beckman LS 6500 scintillation counter.

Generation of tagged DARPP-32 BAC transgenic mice
D1R-DARPP-32/Flag and D2R-DARPP-32/Myc BAC mice were generated
according to the GENSAT BAC modification protocol (Gong et al., 2002). Mouse
DARPP-32 cDNA was amplified from a mouse brain cDNA library (Stratagene). For the
D1R-DARPP-32/Flag mouse, a c-terminal Flag tag (DYKDDDDK) was added to the
mouse DARPP-32 cDNA by PCR and the Flag tagged DARPP-32 construct was inserted
into the S247 shuttle vector using the Asc1/Not1 restriction sites. A Swa1 site was
placed 5’ to DARPP-32 and a 532bp segment of the Drd1a promoter corresponding to the
region right before the start codon (D1 Abox) was cloned into the shuttle vector using the
Asc1 and Swa1 sites. This modified shuttle vector was recombined into the bacterial
artificial chromosome (BAC) containing the full Drd1a promoter. Positive co-integrates
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were double selected by chloramphenicol and ampicillin and verified by PCR. BAC
DNA was then purified and injected into pronuclei from FVB/N oocytes. Detailed
protocols for these procedures can be found at www.gensat.org.
To generate the D2R-DARPP-32/Myc mouse, c-terminal Myc tagged
(SEQKLISEEDL) mouse DARPP-32 cDNA was inserted into the S247 vector using
Asc1/Not1. A Swa1 site was placed 5’ to the DARPP-32 cDNA and a 484bp segment of
the Drd2 promoter corresponding to the region right before the start codon (D2 Abox)
was cloned into the vector using Asc1/Swa1. Venus fluorescent protein cDNA was
excised from the vector and replaced with ECFP cDNA using Nco1/Sal1. This modified
vector was recombined in to the Drd2 BAC and prepared as described above.
Litters were screened for positive transgenics by PCR genotyping from tail DNA
using the primers listed in the following section. Positive mice were backcrossed 10
generations to the C57Bl/6 background. D1R/DARPP-32/Flag and D2R-DARPP32/Myc were then crossed to obtain double transgenic mice expressing both Flag and
Myc tagged DARPP-32. Male mice homozygous for Flag and/or Myc were generated by
interbreeding double transgenic males and females. These homozygous male mice were
subsequently bred to C57Bl/6 females and the heterozygous double transgenic offspring
were used for biochemical experiments.

PCR genotyping from tail DNA
A 0.5cm piece of tail was cut from three week old mice. Tails were lysed
overnight in 500ul of lysis buffer (For 500ml: 50mL 1M Tris, pH 8.8; 25mL of 4M NaCl;
500uL of 1M CaCl2; 5mL of 20% SDS; 419.5mL ddH2O). Lysates were spun down for
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10 min. at 13,000rpm and the supernatant was transferred to a new tube. 500uL of
isopropanol was added to the supernatant, mixed gently, and centrifuged for 5 minutes at
13,000rpm. The supernatant was discarded and 1mL of 70% ethanol was added to the
DNA pellet, mixed gently and centrifuged for 3 minutes at 13,000rpm. The supernatant
was discarded and DNA pellets were dried for 1 hour at 50˚C. Pellets were resuspended
in 150uL of TE buffer (For 500mL: 5mL of 1M Tris, pH 8.0; 1mL of 0.5M EDTA, pH
8.0; 494mL ddH2O).
For PCR genotyping, 0.25uL of purified DNA was added to 8-strip reaction tubes
containing 25uL of Platinum PCR Supermix (Invitrogen) plus 2.5pmol of forward and
reverse primers (see below).

Genotyping PCR primers:
D1R-DARPP-32/Flag mice FOR: AGGTCCTGAAAGGCAGCAG
REV: CTTATCGTCGTCGTCCTTGTAGTC
D2R-DARPP-32/Myc mice FOR: GAGGATGAAGAGGAGGACGA
REV: CAGAAATCAATTTTTGTTCAGAGG
D1R/D2R-DARPP-32 mice Two separate PCR reactions using the Flag and Myc
primers listed above
Floxed DARPP-32 mice

FOR: CTAGTTGTCCTAGGTGTCCTGTGCTCTGTC
REV: CCCTTCAACCTACTGTTAAGACCCTAGCTG

D1R-Cre mice

FOR: AGGGGCTGGGTGGTGAGTGATTG
REV: CGCCGCATAACCAGTGAAACAGC

D2R-Cre mice

FOR: AGCATGCCTTGAAAACACTCCTG
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REV: CACCGGCATCAACGTTTTCTTTTC
D1R-D32-KO mice

Two separate PCR reactions using the Floxed DARPP-32
and D1R-Cre primers listed above

D2R-D32-KO mice

Two separate PCR reactions using the Floxed DARPP-32
and D2R-Cre primers listed above

In situ hybridization
12µm thick sagital sections of fresh frozen brain from wild-type, D1R-DARPP32/Flag and D2R-DARPP-32/Myc single transgenic mice were processed for in situ
hybridization with a 35S labeled antisense riboprobe against full-length GFP using a
protocol described previously (Svenningsson et al., 1998a). Briefly, slides were fixed in
4% paraformaldehyde, and washed twice in 4x SSC buffer. Sections were acetylated for
10 minutes, dehydrated in a series of ethanols, and incubated in a humidity chamber
overnight at 55oC with 2 x 106 cpm of probe per slide mixed in hybridization buffer. The
next day slides were washed 4 times in 4xSSC and incubated with RNAse A for 15
minutes at 37oC. Slides were then washed with a serious of SSC buffers of decreasing
concentration starting with 2x SSC and ending with 0.1x SSC. Sections were dehydrated,
dried, and placed on Kodak MR film for 10 days.
To visualize GFP labeling at the cellular level, slides were dipped in Kodak NTB
emulsion and left in the dark for 6 weeks. Slides were developed and counterstained with
cresyl violet. Pictures of labeled cells were taken on a Zeiss microscope using a 63x
water objective and AxioVision software.
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Fluoro-Gold retrograde labeling
6-8 week old D1R-DARPP-32/Flag and D2R-DARPP-32/Myc mice were
anesthetized with a 1:5 dilution of sodium pentobarbital, 9ul/gram i.p. The mice were
placed in a stereotaxic apparatus (Kopf) and injected bilaterally with 1.0ul of 0.8%
Fluoro-Gold (Fluorochrome, LLC) into the SNpr at a rate of 250nl/minute. Coordinates
for injection into the SNpr were A/P -2.9, M/L +/- 1.5, D/V -4.7 from Bregma. Mice
were perfused 5 days following the injection.

Immunohistochemistry
Mice were perfused transcardially with 1x PBS and 4% paraformaldehyde.
Brains were removed and post-fixed in 4% paraformaldehyde for one hour. Brains were
cryoprotected in sucrose and placed in a mounting block with Neg50 mounting medium
(Richard Allen) and frozen at -80oC until sectioning. 12µm coronal sections were
blocked for one hour in 2% normal serum in 1x PB with 0.25% Triton X-100 (PB-T).
Sections were incubated overnight at 4oC with antibodies against Fluoro-Gold (rabbit
1:3500, Chemicon), GFP (goat 1:1000, gift of Dr. Myriam Heiman), Flag (mouse 1:2000,
Sigma), Myc (goat 1:2500 or 1:10,000, Novus), Tyrosine hydroxylase (TH) (rabbit
1:1000, Chemicon), GFAP (mouse 1:1000, Abcam), DARPP-32 (rabbit 1:2000 Novus),
or NeuN (mouse 1:5000, Chemicon). Slides were washed and incubated with fluorescent
secondary antibodies (1:200) at room temperature for one hour (Fluoro-Gold and TH,
Cy2 conjugated Donkey anti-Rabbit; GFP, Cy3 conjugated Donkey anti-Goat; GFAP,
Cy3 conjugated Donkey anti-Mouse; Flag, FITC conjugated Donkey anti-Mouse; Myc
(Fig. 2c) Cy3 conjugated Donkey anti-Goat; Myc (Fig. 2d) Rhodamine-Red conjugated
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Donkey anti-Goat; DARPP-32, Cy2 conjugated Goat anti-Rabbit; NeuN, Cy3 conjugated
Goat anti-Mouse; all from Jackson ImmunoResearch). Fluorescent images were taken on
a Zeiss confocal microscope using 40x and 63x oil objectives.

Flag and Myc-tagged DARPP-32 immunoprecipitations
Bilateral striata from one mouse (in vivo experiments) or six striatal slices (slice
experiments) were sonicated in 500ul IP lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, Complete Mini protease inhibitors
(Calbiochem), and Halt phosphatase inhibitors (Pierce)). Homogenates were spun down
for 20 minutes at 4oC at 13K rpm. Soluble supernatant was removed and 50 uL/IP of
washed EZView Red anti-Flag M2 affinity gel (Sigma) was added along with 45 uL/IP of
anti-Myc antibody (Novus Biologicals #NB600-338) coupled to magnetic beads
(Dynabeads M-280 Tosylactivated, Invitrogen #142-03). The homogenate/antibody
mixture was gently rotated overnight at 4˚C. The Myc antibody was coupled to the
Dynabeads following the protocol in the product manual; 3ug of Myc antibody was
added for every 5ul of magnetic beads.
Following the overnight incubation, the homogenate/antibody mixture was placed
on a magnetic particle concentrator (MPC, Invitrogen #120-20D) for 1-2 minutes to
separate the Myc magnetic beads from the Flag affinity gel. The supernatant containing
the unbound homogenate and Flag affinity gel was removed to a new tube and kept on ice.
The Myc magnetic beads were washed three times in 1x PBS using the MPC to separate
the beads each time. After the final wash, 30uL of non-reducing sample buffer (Pierce,
#1859594) was added and the beads were boiled for two minutes. Eluted supernatants
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were removed from the beads and added to 7ul of sample buffer reduced with Bmercaptoethanol. Samples were stored at -80˚C until used for immunoblotting.
Flag IP/homogenate mixtures were spun down for 30 seconds at 13K rpm and
unbound supernatant was removed to a fresh tube. This represented the total striatum
sample. 1ul of this unbound supernatant was used in a BCA protein assay (Pierce) to
determine protein concentration for the total striatum sample. Flag affinity gel was
washed three times in 1x PBS and applied to the MPC to remove any residual magnetic
beads. Flag IP’s were eluted and stored at -80˚C as described above.
In addition to the anti-Myc-coupled Dynabeads, anti-Myc-coupled agarose
(Novus Biologicals #NB600-342) was also used for the IP’s with identical results. For
this protocol, Myc-agarose was incubated with the striatal homogenate for 6 hours at 4˚C,
and the Flag-affinity gel was subsequently incubated with the unbound supernatant from
the Myc IP overnight at 4˚C.

Immunoblotting
Samples were loaded onto 10.5-14% Tris-HCl Criterion gels (Bio-Rad), separated
by electrophoresis and transferred to PVDF membranes. Membranes were blocked for
one hour in 5% dry milk in TBS with 0.15% Tween-20 and incubated overnight at 4oC
with phospho-specific primary antibodies against T34 (1:5000, (Valjent et al., 2005) or
T75 (1:7500, (Bibb et al., 1999), or total protein primary antibodies against DARPP-32
(1:10,000, (Hemmings and Greengard, 1986), Flag (1:4000, Sigma), Myc (1:500, Cell
Signaling), Tyrosine hydroxylase (1:1000, Chemicon) or Actin (1:15,000, Abcam).
Antibody binding was revealed by HRP conjugated goat anti-rabbit, goat anti-mouse, or
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donkey anti-goat IgG (1:10,000) and the ECL detection method (PerkinElmer) followed
by exposure on Kodak BioMax film. Membranes blotted previously with phospho-T34
and -T75 antibodies were stripped (Chemicon, Re-blot plus strong stripping buffer) and
re-probed using a monoclonal antibody against DARPP-32 which is not phosphorylation
state specific (Hemmings and Greengard, 1986). Quantification of bands was done by
densitometry, using NIH Image software, version 1.52.

Striatal slice preparation
6-8 week old D1R/D2R-DARPP-32 BAC mice were killed by decapitation. The
brains were rapidly removed and placed in ice-cold, oxygenated Krebs–HCO3− buffer
(124 mM NaCl, 4 mM KCl, 26 mM NaHCO3, 1.5 mM CaCl2, 1.25 mM KH2PO4, 1.5
mM MgSO4 and 10 mM d-glucose, pH 7.4). Coronal slices (350 µm) were prepared
using a vibrating blade microtome, VT1000S (Leica Microsystems). Striata were
dissected from the slices in ice-cold Krebs–HCO3− buffer. Each slice was placed in a
polypropylene incubation tube with 2 ml fresh Krebs–HCO3− buffer containing adenosine
deaminase (10 µg/ml). The slices were preincubated at 30 °C under constant oxygenation
with 95% O2/5% CO2 for 60 min. The buffer was replaced with fresh Krebs–HCO3−
buffer after 30 min of preincubation. Slices were treated with drugs as specified in each
experiment. All drugs were obtained from Sigma-Aldrich. After the drug treatments,
slices were transferred to Eppendorf tubes, frozen on dry ice, and stored at −80 °C until
processed for western blotting.
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In vivo drug treatments – D1R/D2R-DARPP-32 BAC mice
6-8 week old male D1R/D2R-DARPP-32 double transgenic mice were used for
all experiments. Mice were injected i.p. with drug or vehicle and sacrificed 15 minutes
later using focused microwave irradiation. Brains were removed and striata were rapidly
dissected and frozen at -80oC until processing. Drugs used: SKF81297 5mg/kg (Tocris);
Quinpirole 0.2 mg/kg, Caffeine 7.5 mg/kg, Cocaine 25 mg/kg, Haloperidol 1mg/kg,
Clozapine 5 mg/kg (all from Sigma).

Unilateral 6-OHDA lesions and L-DOPA treatment
The procedure used for generating unilateral 6-OHDA lesions in mice has been
previously described (Santini et al., 2007). Mice were anesthetized with a mixture of
midazolam 5 mg/ml (Alpharma) and Hypnorm (Janssen Pharmaceutica) and mounted in
a stereotaxic frame (David Kopf Instruments) equipped with a Cunningham mouseadaptor (Stoelting). 6-OHDA-HCl (Sigma) was dissolved in 0.02% ascorbic acid in
saline at the concentration of 3.0 µg of freebase 6-OHDA/µL. Mice received unilateral
injections (2 x 2 µl) of vehicle or 6-OHDA into the right striatum at the following
coordinates according to the mouse brain atlas: anteroposterior +1.0 mm, mediolateral –
2.1 mm, dorsoventral –3.2 mm; and anteroposterior +0.3 mm, mediolateral –2.3 mm,
dorsoventral –3.2. Each injection was performed at a rate of 0.5 µL/min using a glass
capillary with an outer diameter of ~50 µm attached to a 10 µL Hamilton syringe. After
the injection, the capillary was left in place for an additional 3 min before slowly
retracting it. Mice recovered in their home cage for 3 weeks before beginning drug
treatment. Lesions were assessed at the end of the experiments by determining the striatal
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levels of tyrosine hydroxylase (TH) using Western blotting. Only mice with greater than
a 75% reduction in striatal TH compared to the unlesioned side were used in the final
analysis.
Three weeks post-lesion, mice were injected with either saline or a combination
of L-DOPA (20mg/kg, Sigma) and the peripheral DOPA decarboxylase inhibitor
benserazide (12mg/kg, Sigma) daily for 10 days. On the 11th day, mice were injected
with saline or L-DOPA/benserazide and sacrified 30 minutes later by focused microwave
irradiation. Brains were removed and unilateral striata were dissected. Left and right
sides of the striatum were kept separate and analyzed individually.

Tyrosine hydroxylase DAB immunohistochemistry
Unilateral 6-OHDA injected mice were perfused 3 weeks following the injection
as described above. 20µm coronal sections were washed in 1x PB and incubated for 10
min. in hydrogen peroxide (180uL of 30% H2O2/10mL 1x PBS). Sections were washed
in 1x PB with 0.1% Triton-X 100 (PB-T) and blocked for one hour at room temperature
in 2% normal goat serum in PB-T. Sections were then incubated overnight at 4˚C with a
tyrosine hydroxylase antibody (1:1000, Chemicon). The next day, slides were washed in
PB-T and incubated with biotinylated anti-rabbit secondary antibody (Vector
Laboratories) for one hour at room temperature. Sections were washed again in PB-T
and incubated with Vectastain ABC reagent (Vector Laboratories) for one hour at room
temperature. Sections were washed in 1x PBS, incubated for 5-10 minutes in DAB
reagent (Sigma), washed again in 1x PBS, and coversliped using Permount mounting
medium (Fisher).
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Generation of Floxed DARPP-32 mice
Floxed DARPP-32 mice were generated by Cell & Molecular Technologies, Inc.
Briefly, a targeting vector was generated in which loxP sites were inserted surrounding
exons 1-4 of the mouse DARPP-32 gene. An FRT flanked Neo cassette was inserted
between exon 4 and the 3’ loxP site. The targeting vector included right and left
homology arms which were used to target the construct to the endogenous DARPP-32
locus. The targeted construct was electroporated into ES cells derived from C57Bl/6
mice. Neomycin resistant clones were screened by southern blot for correct homologous
recombination using a 3’ external and a 5’ internal probe and EcoRV digestion. The Neo
cassette was excised in vitro by expression of FLPe recombinase to generate the final
conditional floxed allele. A southern blot strategy was used to detect cells with correct
excision of the Neo cassette. These cells were then used to generate chimeras by
injection into C57Bl/6 blastocysts using standard techniques. Germ line transmission
was confirmed by PCR genotyping and heterozygous floxed DARPP-32 mice were
interbred to generate homozygous floxed DARPP-32 mice. These mice were crossed to
either D1R-Cre or D2R-Cre mice to generate conditional DARPP-32 knock-out mice as
discussed below.

Generation of conditional DARPP-32 knock-out mice
D1R- and D2R-Cre (ER44) lines were generated by the GENSAT project and
characterized previously (Gong et al., 2007b). We obtained male breeders for both of
these lines and bred them with homozygous floxed DARPP-32 female mice. We bred the
heterozygous floxed DARPP-32 D1R- or D2R-Cre positive offspring back to
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homozygous floxed DARPP-32 mice. The resulting homozygous floxed DARPP-32
D1R- or D2R-Cre positive mice were bred again to the homozygous floxed DARPP-32
mice. The resulting offspring were all homozygous floxed and positive or negative for
D1R- or D2R-Cre. Mice negative for Cre were considered wild-types and mice positive
for Cre were considered D1R- or D2R-D32 conditional knock-outs. We continued this
breeding strategy for subsequent generations and mice which were backcrossed at least 4
generations (>90% C57/Bl6) were used in the behavioral analyses.

Open field locomotor behavior
Mice were brought in to the testing room in their home cages at least 1 hour prior
to testing. Female and male mice were kept separate and tested on different days. Mice
were placed in the open field chambers which consisted of 38cm (L) x 25cm (W) x 17cm
(H) white plastic boxes covered with a clear plexiglass lid left open at the edge for
ventilation. Four mice were tested simultaneously using four identical side-by-side
chambers. Locomotor activity was recorded using an overhead Panasonic digital camera
connected to a Dell computer. The mice were tracked using EthoVision software version
3.1 (Noldus) which sampled the x/y location of the mice in the chambers 6 times per
second and recorded the total distance traveled (in centimeters) by each mouse in a given
time period.
For the basal measurement we recorded open field locomotor activity of the mice
for 60 minutes and reported the distance traveled in 3 minute bins. After testing, mice
were removed from the chambers and returned to their home cages. 7 days later, mice
were brought back into the testing room and allowed to habituate for at least one hour.
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Mice were first weighed and then reintroduced to the testing chambers where locomotor
activity was recorded for 21 minutes. After 21 minutes mice were injected i.p. with
either vehicle, cocaine (20 mg/kg, Sigma), or haloperidol (1 mg/kg, Sigma). Recording
was resumed after drug injection for an additional 60 minutes after which mice were
returned to their home cage.
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